"LIPID_ID" "CLASSIFICA" "CHEM_NA" "COMMON_NA" "SYMBOL" "GROUP_NA" "MOL_FORMULA" "FORMULA_C" "FORMULA_H" "FORMULA_O" "FORMULA_N" "FORMULA_P" "FORMULA_S" "MOL_WT" "STR_1" "STR_2" "STR_3" "STR_4" "STR_5" "STR_6" "STR_7" "STR_8" "STR_9" "STR_10" "STR_11" "REF_STR" "MELT_PT" "BOIL_PT" "OPT_ROT" "REFRA_IND" "DENSITY" "SOLUBILITY" "REF_PRP" "UV_SPEC" "IR_SPEC" "NMR_SPEC" "MS_SPEC" "NOTE_SPEC" "REF_SPC" "SOURCE" "REF_SOU" "BIOL_ACTIV" "REF_BA" "NOTE" "REF_NOTE" "GL0001" 8.00 "CONJUGATED GALACTOSYLSPHINGANINE-SERUM ALBUMIN" "CONJUGATED PSYCHOSINE-SERUM ALBUMIN" "12" "C24H49O7N" 24.00 49.00 7.00 1.00 0.00 0.00 463.00 " CH3-(CH2)14-CH-CH-CH2-O-Gal" " ｜ ｜ (REF:001/002)" " OH NH" " ｜" " O" " ｜" " ｴ＼" " ｜ ｳ" " ｸ／" " ｜" "001/002/" "108-110 ﾟC （サイコシンとして）(001)" "001/" "サイコシンとしてのスペクトル：1650 cm-1 (アミドI), 1540 cm-1(アミドII)の消失(001)" "001/" "抗原活性 （抗ジヒドロサイコシン抗体の産生） 定量沈降反応による解析(001) LDLとガラクトシルスフィンゴシン−タンパク質人工抗原の沈降反応 ゲル内沈降反応および定量沈降反応による解析 (002)" "001/002/" "GL0002" 8.00 "II3-NEURAMINOSYLLACTOSYLSPHINGOSINE" "LYSOHEMATOSIDE" "3" "C39H72O19N2" 39.00 72.00 19.00 2.00 0.00 0.00 872.00 " Neuα2-3Galβ1-4Glc-Sph. (REF:006)" "006/" "アミド結合の消失，アミノ基による吸収(6.18μ)の出現 (006)" "006/" "溶血活性はスフィンゴシルフォスホリルコリン，サイコシンおよびリゾレシチン より強い．" "GL0003" 8.00 "GLOBOPENTAOSYLSPHINGOSINE" "LYSO FORSSMAN GLOBOSIDE" "1" "C48H89O25N3" 48.00 89.00 25.00 3.00 0.00 0.00 1107.00 " GalNα1-3GalNβ1-3Galα1-4Galβ1-4Glc-Sph. (REF:007)" "007/" "1600 cm-1の遊離アミノ基の吸収，1650 cm-1 および 1550 cm-1のアミド由来の吸収の消失 (007)" "007/" "GL0004" 8.00 "GALACTOSYLCERAMIDE 3-SULFATE" "GALACTOSYL SULFATIDE" "12" 0.00 0.00 0.00 0.00 0.00 0.00 "Galβ1-1Cer" " 3" " |" " SO3H" "Folch分配における挙動(027)" "027/" "820cm-1(001/029/031)" "EI-MS(033),SI-MS(036)" "001/029/031/033/036/" "ﾋﾄ脳(002/001),ﾋﾄ脳白質と灰白質(009),兎脳白質(057),ﾗｯﾄ脳(017/020),DIAZEPAN長期投与(055),領域分布(020),ﾋﾄ腎(老年者0.39,中年者0.40,若年者0.48mg/g乾燥組織(004),ﾌﾞﾀ膵(031),兎胃(噴門部,幽門部),十二指腸，空腸(053),脳:REVIEW(016),ﾗｯﾄ脳C6ｸﾞﾘｵｰﾏ(032),ﾀﾗ脳(021),ﾗｯﾄ" "002/001/009/057/017/020/055/004/031/053/016/032/021/007/026/033/036/025/039/014/029/034/028/030/049/035/037/018/019/025/041/045/046/051/" "ARYLSULFATASE活性の阻害(003/006/010/011/012/013/016/047/048/054), MYELIN(神経髄梢の絶縁体)の成分(016/023), 多形核白血球に対する酸素ﾗｼﾞｶﾙの生成促進 (024), GLYCOSULFATASEで分解されない(015),ﾏｳｽに対する抗原性 MONOCLONAL ANTI-BODY(043/050),赤血球の LAMINI" "003/006/010/011/012/013/016/047/048/054/023/024/015/043/050/038/040/044/056/042/032/" "AZUR A複合体の吸光度，完全ｱｾﾁﾙ化合物のAZUR A複合体の吸光度(027) 温ﾒﾀﾉｰﾙより沈澱(004) 脱硫酸：METHANOLIC HClﾋﾄ腎SM4Sの脂肪酸組成：22:0,23:0,24:0,24:1,h24:0,h23:0,h24:1(004) K+とのAFFINITY,塩の交換(005/008)ﾗｯﾄ胃粘膜酵素により合成(022) Folch分配" "027/004/005/008/022/052/" "GL0005" 8.00 "GALACTOSYLDIACYLGLYCEROL 3-SULFATE" "SEMINOLIPID, SULFOGALACTOGLYCEROLIPID(SGG)" "12" 0.00 0.00 0.00 0.00 0.00 0.00 "Galβ1-3AAG(DAG)" " 3" " | AAG:1-O-ALKYL-2-O-ACYL-Gro" " SO3H DAG:DIACYL-Gro" "[α]23/D = +2.78(C=1.44 IN C/M 1:1),[α]/D =0 (C=,0.39 IN C/M 1:1)(059)" "ﾋﾟﾘｼﾞﾝ可溶，ｴｰﾃﾙ不溶，熱ﾒﾀﾉｰﾙに可溶であるが冷却により沈澱(058)，Folch分配の挙動(027)" "059/058/027/" "1735cm-1 ｴｽﾃﾙｶﾙﾎﾞﾆﾙ(058)，1240cm-1 C-O-S(058),820cm-1 EQUATORIAL C-O-S(058)875cm-1 TYPE 2b(β)(058),DIACYL型1720cm-1が大きい(061)" "CDCl3/CD3OD,2:1(V/V)中35 OR 60ﾟC: m 5.2ppm:ｸﾞﾘｾﾛｰﾙの2級ﾌﾟﾛﾄﾝ，t 2.3ppm:脂肪酸のα-ﾒﾁﾚﾝ，d 4.35ppm:ANOMERIC(058)" "Gal-ALKYL-Gro(065), SI-MS(036)" "058/061/065/036/" "ﾌﾞﾀ精巣，精子（それぞれ 0.3および 1.0μmol/g)(058/063)，ﾗｯﾄ精巣(087/068)，性成熟日令との関係とｽﾙﾎﾄﾗﾝｽﾌｪﾗｰｾﾞの阻害(073)，ﾗｯﾄ脳(060/061/065/066)， MALE AND FEMALE OF 300g RAT(190nmol/g)(060)，ﾓﾙﾓｯﾄ精巣(059), MOUSE精巣(025)ｳｼ精巣，精子(067)，ﾋﾄ精巣(062" "058/063/087/068/058/063/073/060/061/065/066/059/025/060/059/025/067/062/064/065/021/074/075/043/069/070/037/030/048/049/016/028/" "ARYLSULFATASE活性の阻害(048)， SPERM CAPACITATIONに関与する(072) ﾗｯﾄ脳内[35P]硫酸注射により標識(061)，腹腔内注射により標識(015/066)GLYCOSULFATASEで分解されない(015) MOUSEに対する抗原性(MONOCLONAL ANTIBODY)(043/050) MYELINの成分(069/070)L" "048/072/061/015/066/043/050/069/070/044/" "027/064/058/062/061/071/" "GL0006" 8.00 "LACTOSYLCERAMIDE U/3-SULFATE" "LACTOSYLSULFATIDE" "3" 0.00 0.00 0.00 0.00 0.00 0.00 "Galβ1-4Glcβ1-1Cer" " 3" " |" " SO3H" "Folch分配における挙動(027)" "027/" "1240cm-1が小さい他GALACTOSYL SULFATIDEと等しい(004)" "EI-MS(PERMETHYLATED)(033), SI-MS(036)" "004/033/036/" "ﾋﾄ腎(004)：老年者0.14mg/g，中年者0.18mg/g，若年者0.20mg/g乾燥重量 ﾋﾄ腎(010)，培養腎上皮細胞MDCK(046/019)，JTC-12(019)，MDBK,LLC-PK1(025) TROUT TESTIS(014),SUNCUS(ﾄｶﾞﾘﾈｽﾞﾐ)腎(034)，ﾗｯﾄ腎(026)，ｲﾙｶ腎(039)" "004/010/046/019/025/014/034/026/039/" "ARYLSULFATASE活性の阻害(010/048) LAMININ,THROMBOSPONDIN, von WILLEBRAND FACTORとの結合(044/056) SULPH I MONOCLONAL ANTIBODYと結合(050)""" "010/048/044/056/050/" "完全ｱｾﾁﾙ化誘導体のAZUR A複合体の吸光度(027) 温ﾒﾀﾉｰﾙより冷却後沈澱(004) 50mMHCl/METHANOLで脱硫酸(004)過ﾖｳ素酸酸化ではGalもGlcも抵抗性(004) ﾋﾄ腎SM3の脂肪酸組成(004)：22:0,24:0,24:1,h24:0,h24:1ﾗｯﾄ腎粘膜酵素により合成(022)過ﾖｳ素酸酸化ではGalもGlc" "027/004/022/" "GL0007" 8.00 "GANGLIOTRIAOSYLCERAMIDE U/3-SULFATE" "6" 0.00 0.00 0.00 0.00 0.00 0.00 "GalNAcβ1-4Galβ1-4Glcβ1-1Cer" " 3" " |" " SO3H" "Folch分配における挙動(027)" "027/" "OH:3600-3100cm-1, SULFATE(eq):1230,815cm-1, BETA-ANOMERIC:890cm-1 (076)" "1H-NMR:C/M,2:1,55ﾟC;4.81ppm(3J/1,2=8.0)GalNAc, 4.50ppm(3J/1,2=7.4)Gal, 1H-NMR:DMSO,25ﾟC;4.46ppm(J=7.9)GalNAc, 4.30(J=7.4)Gal, 4.20(J=7.7)Glc(026)" "EI-MS(PERMETHYLATE)(033), SI-MS(036)" "076/026/033/036/" "ﾗｯﾄ腎(076/026)，腎上皮細胞JTC-12(025/077)" "076/026/025/077/" "LAMININ,THROMBOSPONDIN,von WILLEBRAND FACTORとの結合(044/078/056)" "044/078/056/" "完全ｱｾﾁﾙ化物のAZUR A複合体の吸光度(027) HEXOSAMINIDASE AACTIVATORにより分解(077) ﾗｯﾄ脳 GalNAc TRANSFERASEによりGM3から合成(077/078)" "027/077/078/" "GL0008" 8.00 "GANGLIOTRIAOSYLCERAMIDE U/3,V/3-DISULFATE" "6" 0.00 0.00 0.00 0.00 0.00 0.00 "GalNAcβ1-4Galβ1-4Glcβ1-1Cer" " 3 3" " | |" " SO3H SO3H" "Folch分配における挙動(027)" "027/" "硫酸ｴｽﾃﾙ:1240,820cm-1，β-ｱﾉﾒﾘｸ：890cm-1(079)" "1H-NMR(080)" "EI-MS(TRIDEUTERIOMETHYLATED AFTER PERMETHYLATION-SOLUVOLYSIS)(080), Hex:m/z 219+3, Hex-CD3OH:m/z 187(080/033), SI-MS(036)""" "079/080/033/036/" "ﾗｯﾄ腎(079/080)" "079/080/" "LAMININ,THROMBOSPONDIN, von WILLEBRAND FACTORと結合(044)" "044/" "完全ｱｾﾁﾙ化物のAZUR A複合体との結合(027)" "027/" "GL0009" 8.00 "GANGLIOTETRAOSYLCERAMIDE U/3-SULFATE" "SM1a" "6" 0.00 0.00 0.00 0.00 0.00 0.00 "Galβ1-3GalNAcβ1-4Galβ1-4Glcβ1-1Cer" " 3" " |" " SO3H" "Folch分配における挙動(027)" "027/" "EI-MS(PERMETHYLATED)(033)" "033/" "完全ｱｾﾁﾙ化物のAZUR A複合体の吸光度(027) ﾗｯﾄSD1aより酸加水分解により調製(081)" "027/081/" "GL0010" 8.00 "GANGLIOTETRAOSYLCERAMIDE W/3-SULFATE" "SM1b" "6" 0.00 0.00 0.00 0.00 0.00 0.00 "Galβ1-3GalNAcβ1-4Galβ1-4Glcβ1-1Cer" " 3" " |" " SO3H" "1H-NMR(082)" "FAB-MS(082)" "082/" "ﾏｳｽ小腸(044)" "044/" "LAMININと結合(044)" "044/" "GL0011" 8.00 "GANGLIOTETRAOSYLCERAMIDE U/3,W/3-DISULFATE" "SD1a(SB1a)" "6" 0.00 0.00 0.00 0.00 0.00 0.00 "Galβ1-3GalNAcβ1-4Galβ1-4Glcβ1-1Cer" " 3 3" " | |" " SO3H SO3H" "Folch分配における挙動(027)" "027/" "1H-NMR,C/M 1:1,55ﾟC: 4.46ppm(J=7.8Hz)Gal(2分子), 4.74ppm(J=7.4Hz)GalNAcIN DMSO,60ﾟC: 4.51ppm(J=8.0) GalNAc, 4.32ppm(J=8.1)末端Gal, 4.33ppm(J=7.8) 内部Gal(081)" "EI-MS(PERMETHYLATED) m/z 222:3-DEUTERIOMETHYLATED-2,4,6-TRIMETHYL-Gal, m/z 187:222-CD3OH (081/033) SI-MS(036)" "081/033/036/" "ﾗｯﾄ腎(081)，ﾋﾄ肝癌細胞PLC/PRF/5(083)" "081/083/" "LAMININ, THROMBOSPONDIN, von WILLEBRAND FACTORと結合(044) MONOCLONAL ANTIBODY 2H6G5(IgM)および4A9E10(IgG3)と結合(083)""" "044/083/" "完全ｱｾﾁﾙ化物のAZUR A複合体の吸光度(027)" "027/" "GL0012" 8.00 "GLOBOTETRAOSYLCERAMIDE W/3-SULFATE" "1" 0.00 0.00 0.00 0.00 0.00 0.00 "GalNAcβ1-3Galα1-4Galβ1-4Glcβ1-1Cer" " 3" " |" " SO3H" "1240,810:SULFATE(056)" "1H-NMR(ANOMERIC PROTONS)(056)" "NEGATIVE SI-MS(056)" "056/" "ﾋﾄ腎(056)" "056/" "THROMBOSPONDINとの結合(056)" "056/" "GL0013" 8.00 "GLOBOPENTAOSYLCERAMIDE X/3-SULFATE" "Gb5Cer X/3-SULFATE" "1" 0.00 0.00 0.00 0.00 0.00 0.00 "Galβ1-3GalNAcβ1-3Galα1-4Galβ1-4Glcβ1-1Cer" " 3" " |" " SO3H" "1240cm-1:SO STRETCHING, 810cm-1:C-O-S VIBRATION(084)" "1H-NMR:H-1〜H-4 DOUBLE RELAYED COSY(084)" "NEGATIVE SI-MS(084)" "084/" "ﾋﾄ腎(084)" "084/" "THROMBOSPONDINとの結合(084)" "084/" "GL0014" 8.00 "W(/3-SULFO-β-D-GLUCURONOSYL)-LACTONEOTETRAOSYLCERAMIDE" "4" 0.00 0.00 0.00 0.00 0.00 0.00 "GlcUβ1-3Galβ1-4GlcNAcβ1-3Galβ1-4Glcβ1-1Cer" " 3" " |" " SO3H" "FAB-MS: PERTRIMETHYLSILYLATED DESULFATED OR PERMETHYLATED DESULFATED DERIVATIVE(085)" "085/" "ﾋﾄ末梢神経(085)" "085/" "神経細胞接着因子，ﾐｴﾘﾝ糖蛋白質などとの共通抗原(085)" "085/" "GL0015" 8.00 "Y(/3-SULFO-β-D-GLUCURONOSYL)-NEOLACTOHEXAOSYLCERAMIDE" "4" 0.00 0.00 0.00 0.00 0.00 0.00 "GlcUβ1-3Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ1-3Galβ1-4Glcβ1-1Cer" " 3" " |" " SO3H" "ﾋﾄ末梢神経(085)" "085/" "GL0016" 8.00 "3-SULFOGALACTOSYL-(1-3)-sn-1-ALKYLGLYCEROL" "LYSO-SEMINOLIPID" "12" 0.00 0.00 0.00 0.00 0.00 0.00 "Galβ1-3 ALKYL-Gro" " 3" " |" " SO3H" "Folch分配における挙動(027)" "027/" "SI-MS(036)" "036/" "ﾌﾞﾀ精巣(058)，脳(016)，ﾋﾄ精巣SEMINOLIPIDから弱ｱﾙｶﾘ処理により調製(064)" "058/016/064/" "ﾗｯﾄ肝二次ﾘｿｿｰﾑのﾘﾊﾟｰｾﾞによりｾﾐﾉﾘﾋﾟﾄﾞから生成(086)" "086/" "完全ｱｾﾁﾙ化物のAZUR A複合体の吸光度(027) TLC移動度(058) ﾓﾙﾓｯﾄ精巣より弱ｱﾙｶﾘ加水分解産物として(059)ﾌﾞﾀ精子より弱ｱﾙｶﾘ加水分解産物として(063) SULPH I MONOCLONAL ANTIBODYとの結合(050)" "027/058/059/063/050/" "GL0017" 8.00 "GalDAG, GALACTOSYLDIACYLGLYCEROL, MONOGALACTOSYLGLYCERIDE" "12" 0.00 0.00 0.00 0.00 0.00 0.00 "Galβ1-3DAG" " DAG:DIACYLGLYCEROL" "ﾌﾞﾀ精巣(058)，ﾀﾗ脳(90%以上がｼﾞｱｼﾙ型)(021/074),ﾗｯﾄ脳（脂肪酸組成:16:0,43.8%;18:1,23.4%; 18:0,20.9%)(060)，ﾋﾄ脳(009)，DIAZEPAM長期投与ﾗｯﾄ脳(055)， ｶｴﾙ脳(029)，ﾗｯﾄ脳 部位分布，ﾋﾂｼﾞ脳細胞分画(020)，胎生期ﾗｯﾄ脳初代培養(037)，SCHWANN CELL由来培養細胞株(04" "058/021/074/060/009/055/029/020/037/049/" "GL0018" 8.00 "GalAAG,GALACTOSYLALKYLACYLGLYCEROL, MONOGALACTOSYLGLYCERIDE" "13" 0.00 0.00 0.00 0.00 0.00 0.00 "STEIM67BBAはDAG型" "ﾌﾞﾀ精巣（Ｘ物質）(058)，ﾗｯﾄ精巣(087/071)，ｶｴﾙ脳(029)，ﾋﾄ精巣(064)，ﾗｯﾄ脳：脂肪酸組成：16:0,33.1%;18:1,26.6%;18:0,21.7% (060)" "058/087/071/029/064/060/" "ﾎｳ酸含有TLC(058) RAT TESTISでのIN VIVO生合成(071)" "058/071/" "GL0019" 8.00 "GALACTOSYLCERAMIDE 6-SULFATE" "12" 0.00 0.00 0.00 0.00 0.00 0.00 " SO3H" " |" " 6" "Galβ1-1Cer" "165-170 (088)" "[α]/589 = -0.4 (2.4% IN PYRIDINE)(088)" "ｱｾﾄﾝに難溶(088)" "088/" "3-硫酸誘導体とほとんど等しい(088)" "088/" "合成(088)" "088/" "LAMININ,THROMBOSPONDIN,von WILLEBRAND FACTORとの結合(044)" "044/" "ｹｲ酸ｶﾗﾑにてｾﾚﾌﾞﾛｼﾄﾞと十分分離できる(088) TLC（中性溶媒）で3-硫酸と分離不可能(058) 過ﾖｳ素酸で完全に分解される" "088/058/" "GL0020" 8.00 "8-SULFO-N-GLYCOLYLNEURAMINYL-(α2-6)-GLUCOSYL-(1-8)-N-GLYCOLYLNEURAMINYL-(α2-6)-GLUCOSYL-(1-1)-CERAMIDE" "13" 0.00 0.00 0.00 0.00 0.00 0.00 "NeuGcα2-6Glc1-8NeuGcα2-6Glc1-1Cer" " 8" " |" " SO3H" "1220cm-1: S=O STRETCHING OF SULFATE, 800cm-1: C-O-S VIBRATION OF SULFATE(089)" "KARLSSONに従い完全ﾒﾁﾙ化−還元−TMS誘導体として(089)" "089/" "ｳﾆ(STRONGYLOCENTROTUS INTERMEDIUS)卵および胚(089)" "089/" "ｱﾐﾝなどの毒性物質から胚細胞を保護する(089)" "089/" "HYDROXY AND NONHYDROXY FATTY ACIDS(089) LCB:t18:0(089) 硫酸基を持つｼﾞｼｱﾛｶﾞﾝｸﾞﾘｵｼﾄﾞの最初の構造(089)" "089/" "GL0021" 8.00 "8-SULFO-N-GLYCOLYLNEURAMINOSYL-(α2-6)-β-D-GLUCOPYRANOSYL-(1-1)-CERAMIDE" "GlcCer I/6-(8-SULFO-NeuGc)" "12" 0.00 0.00 0.00 0.00 0.00 0.00 " SO3H" " |" " 8" "NeuGcα2-6Glcβ1-1Cer" "1283cm-1: S-O VIBRATION, 810cm-1: S-O BOND(090)" "ASIALO化合物の全ﾒﾁﾙ化物(090)" "090/" "ｳﾆ(ECHINOCARDIUM CORDATUM), GONADS(090)" "090/" "LCB: t18:0,t16:0,t17:0(090) FATTY ACIDS:15:0,h24:0,h22:0,h22:1,h18:0,h23:0(090) NeuAcを持つ分子種もある(090) 硫酸基を持つｶﾞﾝｸﾞﾘｵｼﾄﾞの最初の構造(090)硫酸基を持つｶﾞﾝｸﾞﾘｵｼﾄﾞの最初の構造(090)" "090/" "GL0022" 8.00 "3-SULFOGALACTOSYL-β-(1-1)-SPHINGOSINE" "LYSOSULFATIDE" "12" 0.00 0.00 0.00 0.00 0.00 0.00 "Galβ1-1Sph" " 3" " |" " SO3H" "ﾗｯﾄ胃粘膜酵素によりPSYCHOSINEより合成(022)" "022/" "SULFATASEによる加水分解(048) 抗体SULF Iの結合(050)" "048/050/" "GL0023" 8.00 "α,α'-TREHALOSE 2,3,6,6'-TETRAESTER-2'-SULFATE(AMMMONIUM SALT)" "MYCOBACTERIAL SULFOLIPID I" "13" "C145H275O20NS" 145.00 275.00 20.00 1.00 0.00 1.00 2381.00 " R R'''" " | |" " 6 6" "Glcα1-1Glcα R,R',R'',R'''=FATTY ACIDS" " 2 2 3" " | | |" " SO3H R R''" "[α]25/ =40.5 (091)" "091/" "1400-1450cm-1:NH OF AMMONIUM SALT, 1660-1740cm-1:ACYL CARBONYL, 1250cm-1:SO824cm-1:SO, 808cm-1:TYPE 3 (091)" "091/" "MYCOBACTERIUM TABERCULOSIS(091)" "091/" "皮内注射で毒性(091)" "091/" "SPONTANEOUS DESULFATION(091) DEACYLATION TO YIELD TREHALOSE 2-SULFATE(092)" "091/092/" "GL0024" 8.00 "GLUCOSYLCERAMIDE 3-SULFATE" "GLUCOSYL SULFATIDE" "12" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 "Glcβ1-1Cer" " 3" " |" " SO3H" "1230cm-1: S=O STRECHING, 815cm-1: C-O-S VIBRATION (093)" "1H-NMR:DOUBLE RELAYED COSY" "SI-MS (M-H)/-" "093/" "ﾗｯﾄ腎(093)" "093/" "GL0025" 8.00 "2,3-DIPHYTANYL-1-[6-HSO3-α-MANNOPYRANOSYL-1-2-α-GLUCOPYRANOSYL]-sn-GLYCEROL" "S-DGD" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " Manα1-2Glcα1-1-sn-DPG (101)" " 6" " ｜ DPG: DIPHYTANYLGLYCEROL" " SO3-NH4+ (C20-C20 AND C20-C25)" "101/" "830cm-1 (C-O-S)(101)" "IH-NMR (103)" "NEGATIVE FAB (NH4 SALT) [M-1]- 1073, [M-NH4]- 1055(103)" "101/103/" "Halococcus saccharolyticus, Extremely halophilic bacterium strain R-4（極 性脂質の29重量%）(101), Extremely halophilic bacteria strains Gla-2.2, M-2.5,M-2.38; (102)" "101/102/" "培地塩濃度の増加とともに増加(102)" "102/" "strain R-4ではこの硫糖脂質が存在する代わりにﾎｽﾌｧﾁｼﾞﾙｸﾞﾘｾﾛｰﾙ硫酸を欠く(101)" "101/" "GL0026" 8.00 "2,3-DIPHYTANYL-1-[α-MANNOPYRANOSYL-1-2-α-GLUCOPYRANOSYL]-sn-GLYCEROL" "DGD" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " Manα1-2Glcα1-sn-DPG (101/112)" " DPG: DIPHYTANYLGLYCEROL" " (C20-C20 AND C20-C25)" "101/112/" "[α]/D +59.43ﾟ, [M]/D 581 (112)" "112/" "Extremely halophilic bacterium strain R-4 (101)Extremely halophilic strains Gla-2.2, Y-27, Gaa-3, Gaa-6, Gca-19, M-2.5, Ma-2.38; H. vallismortis, H. marismortui, H. salinarium, H. cutirubrum(102)Halobacterium cutirubrumの硫酸化3糖ｼﾞﾌｨﾀﾆﾙｸﾞﾘｾﾘﾙ" "102/112/" "GL0027" 8.00 "PHOSPHOLIPID I" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " Glcα1-2Galβ1-1DBPG-P-sn-3-GRO (104)" " DBPG: DIBIPHYTANYLGLYCEROL" "104/" "1220cm-1(P=O), 1110cm-1(P-O- + C-O-C), 1050cm-1(P-O-C)(104)" "IH-NMR 30ﾟC, ｸﾛﾛﾎﾙﾑｰﾒﾀﾉｰﾙ 3.37ppm CH2-O-, 3.77ppm CH-O- 13C-NMR 99.1ppm αｰGlcp, 106.7ppm β-Galf (104)""" "ORD: MD +137ﾟ(calc'd +202ﾟ)(104)" "104/" "Methanospirillum hungatei GP1,総糖脂質の50% (wt%)" "M. hungateiのphosphatidylglycerolはhalophilic bacteriaのものと光学的な立体 構造が逆で2,3-di-O-phytanyl-sn-glycerol-1-phosphoryl-1'-sn-glycerolである （末端Gro-Pはその他の生物と同じ）．これに対してphosphoglycolipid I のGro-Psn-sn-3'configurationであって" "104/" "GL0028" 8.00 "PHOSPHOLIPID II" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " Galβ1-6Galβ1-1DBPG-P-sn-3-GRO (104)" " DPG: DIBIPHYTANYLGLYCEROL" "104/" "図 (104)" "13C-NMR 109.0(βｰGalf), 108.4(β-Galf)(104)" "ORD: MD -352ﾟ (104)" "104/" "Methanospirillum hungatei GP1, 主要糖脂質，総脂質の14% (wt%)" "GL0029" 8.00 "GENTIOBIOSYLCALDARCHAEOL" "GENTIOBIOSYLCARDARCHAEOL" "C98H192O16" 98.00 192.00 16.00 0.00 0.00 0.00 1624.00 " CH3 CH3 CH2-OH" " | | |" " HCH-O-(CH2)2-{CH-(CH2)3}3-CH-(CH2)2-{CH-(CH2)3}3-CH-(CH2)2-O-CH" " | CH3 CH3 | | |" " | | | CH3 CH3 |" " CH-O-(CH2)2-{CH-(CH2)3}3-CH-(CH2)2-{CH-(CH2)3}3-CH-(CH2)2-O-CH2" " | | |" " O-CH2 CH3 CH3" " |" " 1βGlc6-1βGlc (REF:016)" "016/" "GL0030" 8.00 "1-O-HEXADECYL-2-PALMITOYL-3-[β-3'-SULFOGALACTOSYL]GLYCEROL" "SEMINOLIPID" "C41H79O41S" 41.00 79.00 41.00 0.00 0.00 1.00 1259.00 " Galβ1-O-CH2 O (REF:018)" " 3 | ‖" " | CH-O-C-(CH2)14-CH3" " NaSO3 |" " CH2-O-(CH2)15-CH3" "018/" "820cm-1:硫酸ｴｽﾃﾙ, 875cm-1:ﾍｷｿﾋﾟﾗﾉｼﾄﾞのβｱﾉﾏｰ構造" "DESULFATED AND DEACYLATED SGGをTMS化してGC-MS(019)" "019/" "雄の豚の睾丸(018)，精子(018)，ラット脳(019)" "018/019/" "不明" "GL0031" 8.00 "2,3-DI-O-PHYTANYL-1-O-[α-D-GLUCOPYRANOSYL-(1'-2')-O-β-D-GALACTOFURANOSYL]-sn-GLYCEROL" "DGD-I" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " Glcα1-2Galβ1-1DPG (104)" " DPG: DIPHYTANYLGLYCEROL" "104/" "1110cm-1(C-O-C), 1050cm-1(C-OH), 1385, 1375cm-1(ISOPROPYL)(104)" "IH-NMR 3.2-4.4ppm (-CH2-O-, -CH-O-) 13C-NMR 98.5ppm: αｰGlcp, 106.1ppm: β-Galf(104)" "ORD OF DIPHYTANYLGLYCEROL: [α]/D +8.6ﾟ ORD OF INTACT GLYCOLIPID: [α]/D= +150ﾟ (104)" "104/" "Methanospirillum hungatei GP1, 主要糖脂質，総脂質の17% (wt%)" "GL0032" 8.00 "2,3-DI-O-PHYTANYL-1-O-[β-D-GALACTOFURANOSYL-(1'-6')-β-D-GALACTOFURANOSYL]-sn-GLYCEROL" "DGD-II" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " Galβ1-6Galβ1-1DPG (104)" " DPG: DIPHYTANYLGLYCEROL" "104/" "1110cm-1(C-O-C), 1050cm-1(C-OH)(104)" "ORD OF INTACT GLYCOLIPID: [α]/D= -369ﾟ (104)" "104/" "Methanospirillum hungatei GP1, 微量糖脂質，総脂質の2% (wt%)" "GL0033" 8.00 "DGT-I" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " Glcα1-2Galβ1-1DBPG (104)" " DBPG: DIBIPHYTANYLGLYCEROL" "104/" "1110cm-1(C-O-C), 1050cm-1(C-OH)(104)" "ORD: MD +221ﾟ (Calc'd +205ﾟ)(104)" "104/" "Methanospirillum hungatei GP1, 微量糖脂質，総脂質の0.5% (wt%) (104) Caldariella acidophila （部分構造）(105)" "104/105/" "GL0034" 8.00 "DGT-II" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " Galβ1-6Galβ1-1DBPG (104)" " DBPG: DIBIPHYTANYLGLYCEROL" "104/" "1110cm-1(C-O-C), 1050cm-1(C-OH)(104)" "ORD: MD -227ﾟ (Calc'd -322ﾟ)(104)" "104/" "Methanospirillum hungatei GP1, 微量糖脂質，総脂質の0.2% (wt%)" "GL0035" 8.00 "O-2-ACYLAMID0-2-DEOXY-β-D-GLUCOPYRANOSYL PENTACYCLIC TETROL" "GLYCOLIPID B" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " PCT: HO-C-(CHOH)3-CH2-CH2" " GlcNacylβ1-1PTC ＼ｶｼｻ" " ／ｼｲｱｲｱｲ" " CH3 ｵ ｵｶ" " (A FULLY SATURATED 35-CARBON PENTACYCLIC ｲｬｲｫｲｫｲ" " TRITERPENE DERIVED TETROL) ｵ ｵ ｵ" " ｲｱｲｱ" " ｱｲ" "1645cm-1: ｱﾐﾄﾞ, 1545cm-1: ｱﾐﾄﾞ (107)" "107/" "Bacillus acidocaldarius (16.7% of total lipid or 26.0% of glycolipid) (107)" "107/" "本菌はpH3,60ﾟCという過酷な条件で生存するため膜構成に関して特殊な構造を持っ ていると考えられる(107)" "107/" "GL0036" 8.00 "O-β-D-GLUCOPYRANOSYL-(1-4)-O-2-ACYLAMID0-2-DEOXY-β-D-GLUCOPYRANOSYLDIACYLGLYCEROL" "GLYCOLIPID C" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " Glcβ1-4GlcN'acylβ1-1(3)-DAG ( )" " DAG: DIACYLGLYCEROL" "1730cm-1: ｱｼﾙｴｽﾃﾙ, 1645cm-1: ｱﾐﾄﾞ, 1545cm-1: ｱﾐﾄﾞ (107)" "107/" "Bacillus acidocaldarius (15.9% of total cell lipid or 24.9% of gycolipid) (107)" "107/" "GL0037" 8.00 "O-β-D-GLUCOPYRANOSYL-(1-4)-O-2-ACYLAMID0-2-DEOXY-β-D-GLUCOPYRANOSYLMONO-ACYLGLYCEROL" "GLYCOLIPID D" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " Glcβ1-4GlcNacylβ1-1(3)-MAG ( )" " MAG: MONOACYLGLYCEROL" "Bacillus acidocaldarius : 26.5% of total lipid or 41.3% of gycolipid (107)" "107/" "GL0038" 8.00 "6-SULFO-α-D-QUINOVOPYRANOSYL-(1-1')-2',3'-DI-O-ACYL-D-GLYCEROL" "ACIDIC LIPID K" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " Quiβ1-1(3)DAG (107)" " 6" " ｜ Qui: 6-DEOXY-D-GLUCOSE" " SO3 DAG: DIACYLGLYCEROL" "107/" "1160cm-1: ｽﾙﾎﾝ酸, 1030-1050cm-1: ｽﾙﾎﾝ酸, 1730cm-1: ｱｼﾙｴｽﾃﾙ (107)" "IH-NMR 4.87ppm: H-1　13C-NMR(123)" "FDMS m/z 601(M+Na)+ (123)" "ｱﾝｽﾛﾝ硫酸による発色: 592nm (107)" "107/123/" "Bacillus acidocaldarius :43.2% of the acidic lipid fraction (107) ﾑﾗｻｷｳﾆ shell: 30nmole/g (123), ｱｶｳﾆ，卵および精子 (124)" "107/123/124/" "分子種の決定(hydrazinolysis)(122)" "122/" "GL0039" 8.00 "2,3-DI-PHYTANYL-1-O-[β-D-GLUCOPYRANOSYL-(1'-6')-O-α-D-MANNOPYRANOSYL-(1'-2')-O-α-D-GLUCOPYRANOSYL]-sn-GLYCEROL" "TDG-2" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " Glcβ1-6Manα1-2Glcα1-1-DPG (108/109)" " DPG: 2,3-DI-O-PHYTANYL-sn-GLYCEROL" "108/109/" "IH-NMR 4.95ppm=βｰGlc H-1 4.47ppm=α-Glc H-1, α-Man H-1(108)" "[α]/D +8ﾟ FOR DIETHER MOIETY [α]24/D +34.6ﾟ FOR THE TRIGLYCOSYL DIETHER(108)" "108/" "Halobacterium marismortui, 11mol% of total lipid (108)" "108/" "GL0040" 8.00 "S-TeGD (GL-1)" "C67H131O26NS" 67.00 131.00 26.00 1.00 0.00 1.00 1397.00 " Galβ1-6Manα1-2Glcα1-1-DPG (109)" " 3 3" " ｜ ｜ DPG: 2,3-DI-O-PHYTANYL-sn-GLYCEROL" " SO4- 1Galα" "109/" "3400cm-1: OH, 2920cm-1: CH2, 1450cm-1: CH3, 1380cm-1: ISOPROPYL DOUBLET 1100cm-1: C-O-C DIETHYL ETHER, 1245cm-1: SULFATE S=O, 815cm-1: SULFATE S-O-C(109)" "[α]/D +52.0, [M]/D +733 (109)""" "109/" "Halobacterium cutirubrum: 1.5-2.5% of the total polar lipids (109)" "109/" "GL0041" 8.00 "TeGD-1 (GL-2)" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " Galβ1-6Manα1-2Glcα1-1-DPG (109)" " 3" " ｜ DPG: 2,3-DI-O-PHYTANYL-sn-GLYCEROL" " 1Galα" "109/" "Halobacterium cutirubrum: 0.5% of the total polar lipids (109)" "109/" "GL0042" 8.00 "TGD-1 (GL-3)" "C61H118O18" 61.00 118.00 18.00 0.00 0.00 0.00 1138.00 " Galβ1-6Manα1-2Glcα1-1-DPG (109/112)" " DPG: 2,3-DI-O-PHYTANYL-sn-GLYCEROL" "110/" "[α]/D +46.8 (109) [α]/D +47.02 (112) [M]/D +533 (109) [M]/D 536 112)" "109/112/" "Halobacterium cutirubrum: 5% of the total polar lipids(109)" "109/" "GL0043" 8.00 "C76H140O25N" 76.00 140.00 25.00 1.00 0.00 0.00 1466.00 " Galβ1-2Galα1-6GlcNacylβ1-2Glcα1-3(1)-DAG (110)" "110/" "1545cm-1: AMIDE I, 1640cm-1: AMIDE II (110)" "1H-NMR 0.85: ISO-METHYL, 2.1: N-ACETYLMETHYL(110)" "[α]22/D +38.5±0.5ﾟ (110)" "110/" "Flavobacterium thermophilum: 8.6% of dry cell" "本菌は総脂質の71%にものぼる糖脂質を含む" "GL0044" 8.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " Man24-Glc-DPG (111)" " DPG: DI-O-PHYTANYLGLYCERYL ETHER" "111/" "Thermoplasma acidophilum (111)" "111/" "本菌は59ﾟC，pH2で生育．Mycoplasma tales に属す(111)" "111/" "GL0045" 8.00 "2,3-DI-O-PHYTANYL-1-O-[β-D-GALACTOPYRANOSYL-3'-SULFATE-(1'-6')-O-α-D-MANNOPYRANOSYL-(1'-2')-O-α-D-GLUCOPYRANOSYL]-sn-GLYCEROL" "S-TGD-1" "C61H121O21NS" 61.00 121.00 21.00 1.00 0.00 1.00 1235.00 " Galβ1-6Manα1-2Glcα1-1-sn-DPG (112)" " 3" " ｜" " SO3- DPG: 2,3-DI-PHYTANYL-sn-GLYCEROL" "112/" "1265cm-1: S=O, 830cm-1: S-O-C(112)" "1H-NMR" "NH4塩の[α]/D +46.79ﾟ, NH4塩の[M]/D +578.7" "112/" "Halobacterium cutirubrum, 極性脂質の24% (112)" "112/" "GL0046" 8.00 "C49H98O8" 49.00 98.00 8.00 0.00 0.00 0.00 814.00 " Glcα1-1-sn-DPG (112)" " DPG: 2,3-DI-O-PHYTANYL-sn-GLYCEROL" "112/" "3400cm-1: OH, 1370cm-1: ISOPROPYL, 1110cm-1: C-O-C(112)" "[α]/D +41.36ﾟ, [M]/D 337 (112)" "112/" "Halobacterium cutirubrumのsulfated triglycosyl dietherの部分加水分解物" "GL0047" 8.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " Galα1-6Galβ1-3-sn-DAG (113)" " DAG: 2,3-DI-O-ACYLGLYCEROL" "113/" "FAB-MS: 分子種 (113)" "113/" "The acidophilic alga Dunaliella acidophila(乾燥重量の0.6%) (113) Major molecular species: 18:3/16:2, 18:3/16:1, and 18:3/16:0 (113)" "113/" "分子種の決定" "GL0048" 8.00 "2,3-DI-O-PHYTANYL-sn-GLYCERO-1-PHOSPHORYL-1'-MYO-L-INOSITOL" "PID" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " L-myo-INOSITOL-1-O-P-O-sn-DPG (114)" " DPG: 2,3-DI-O-PHYTANYLGLYCEROL" "114/" "[α]20/D +2.3ﾟ (114)" "114/" "Pyrococcus woesei(Thermococcales,一種の古細菌):90%(W/W) of total polar lipids" "P. woeseiは100-103ﾟCで生育" "GL0049" 8.00 "2,3-DI-O-PHYTANYL-sn-GLYCERO-1(α-D-GLUCOPYRANOSYL-3-PHOSPHATE)" "PGD" "C49H99O11P" 49.00 99.00 11.00 0.00 1.00 0.00 893.00 " -" " PO3-O-3Glcα1-1-sn-DPG (114)" " DPG: 2,3-DI-O-PHYTANYLGLYCEROL" "114/" "1365-1375cm-1: ISOPROPYL DOUBLET 1255,1060cm-1: PHOSPHATE 1085cm-1: C-O-C 伸縮 (114)" "13C-NMR 69.3, 70.3, 70.4, 70.9, 78.1: -CH2-O- AND CH-O- 98.3ppm: C-1(α), C-3は3ppm低磁場SHIFT 1H-NMR 4.98ppm, J1,2 1.0Hz (H-1, Glcα) (114)""" "POS-FAF: m/z 916: M+Na+ NEG-FAB: m/z 893: M-H+ (114)" "[α]20/D +34ﾟ (114)" "114/" "AN1株(Thermococcales,一種の古細菌): 40% of total polar lipids(114)" "114/" "GL0050" 8.00 "2,3-DI-O-PHYTANYL-1-O-[β-D-GLUCOPYRANOSYL]-sn-GLYCEROL" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " Glcβ1-1-sn-DPG (116)" " sn-DPG: 2,3-DI-O-PHYTANYL-sn-GLYCEROL" "116/" "13C-NMR (ﾍﾞﾝｾﾞﾝ/ﾒﾀﾉｰﾙ, 7:1, 室温) 103.87ppm C-1, β-Glcp (1J 159Hz) (116)" "NEGATIVE FAB-MS (116)" "DI-O-PHYTANYLETHER: M/D=+56.1" "116/" "Methanococcus voltae: 2.8%(W/W) of total polar lipids (116)" "116/" "GL0051" 8.00 "2,3-DI-O-PHYTANYL-1-O-[β-D-GLUCOPYRANOSYL-(1-6)-β-D-GLUCOPYRANOSYL]-sn-GLYCEROL" "C55H108O13" 55.00 108.00 13.00 0.00 0.00 0.00 976.00 " Glcβ1-6Glcβ1-1-sn-DPG (116/117)" " sn-DPG: 2,3-DI-O-PHYTANYL-sn-GLYCEROL" "116/117/" "13C-NMR(116) 103.84: C-1, Glcp 104.12: C-1', Glcp 1H-NMR (116) J1,2: 7.8 AND 7.6 13C-NMR(117) 70.45: C-6内側Glcp 62.82: C-6内側Glcp""" "FAB-MS DI-O-ALKYLGLYCERYLETHER m/z 653.9:(M+1) INTACT LIPID M/z 999.77: [M+Na], m/z 1015.7:[M+K] (117)" "116/117/" "Methanococcus voltae: 62.5%(W/W) of total polar lipids (116) Methanobacterium thermoautotrophicum(117)" "116/117/" "M. thermoautotrophicumの脂質には一分子のK+またはNa+が結合している (117)" "117/" "GL0052" 8.00 "2,3-DI-O-PHYTANYL-1-[PHOSPHORYL-2-ACETAMIDO-2-DEOXY-β-D-GLUCOPYRANOSYL]-sn-GLYCEROL" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " GlcNAcβ1-P-1-sn-DPG (116)" " sn-DPG: 2,3-DI-O-PHYTANYLGLYCEROL" "116/" "FT-IR 1240cm-1: P=O, 1040cm-1: P-O-C, 1740cm-1: C=O, 1360,1380cm-1: ISOPROPYL 1550cm-1: AMIDE STRETEH(116)" "13C-NMR 94.54: C-1, 2J(C,P)=7.4Hz 54.61: C-2, 3J(C,P)=7.5Hz 1H-NMR 1.85ppm: CH3(ACETOAMIDE), 3J1,2=10.5Hz (116)""" "NEGATIVE FAB-MS m/z 934:[M-H]-, m/z 935:[M]- (116)" "[M]/D=-533.04(116)" "116/" "Methanococcus voltae: 7.2%(W/W) of total polar lipids (116)" "116/" "GL0053" 8.00 "GENTIOBIOSYL CALDARCHAEOL" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " Glcβ1-6Glcβ1-1-C40-TETRAETHER (118/120)" "118/120/" "1100cm-1: C-O-C, 1035cm-1: C-OH (118)" "POSITIVE FAB-MS m/z 1648.4:[M+Na]+, m/z 1649.0:[M+Na+1]+ (118)" "118/" "Methanobacterium thermo auto trophicum (118)" "118/" "GL0054" 8.00 "GENTIOBIOSYLCALDARCHAETIDYL ETHANOLAMINE" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " Glcβ1-6Glcβ1-1-C40-TETRAETHER-PHOSPHOEHTANOLAMINE (118/120)" "118/120/" "Fig. 1C (118)" "POSITIVE FAB-MS m/z 1,749.4 [M+1]+, m/z 1,748.7 [M]+ (118)" "118/" "GL0055" 8.00 "1,2(2,3)-DI-O-ACYL-3(1)-α-GALACTOPYRANOSYL-GLYCEROL" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:126/127/128)" " Galpα1-3(1)-SN-DAG" " DAG: DIACYLGLYCEROL" "126/127/128/" "1H-NMR (132)" "132/" "TREPONEMA PALLIDUM KAZAN 5 AND OTHER TREPONEMAS: THE MAJOR COMPONENT=9.5% OF DRY CELL(126/127) TREPONEMA HYODYSENTERIAE B78:29.9% OF THE TOTAL LIPID. THE TOTAL LIPID WAS16.4% OF THE CELL DRY WEIGHT. SATURATED C14-C16 CHAINS COMPRIZED MORE THAN 95% OF" "129/130/" "THE MAJOR PHOSPHOLIPID OF TREPONEMA WAS PHOSPHATIDYLGLYCEROL AND DIPHOSPH-ATIDYLGLYCEROL. GLYCOLIPIDS COULD NOT BE DETECTED IN LEPTOSPIRAE.(127) THE PREPARATION FROM T. HYODYSENTERIAE CONTAINED 1-ALK-1-ENYL FROM (88.3%)AND AN ADDITIONAL FATTY ACYL ESTER" "127/" "GL0056" 8.00 "1,2-DI-O-ACYL-3-[6-O-ACYL-βGALACTOPYRANOSYL]-SN-GLYCEROL" "ACYLMONOGALACTOSYLDIACYLGLYCEROL" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:131/132/133)" " Acyl-6-Galpβ1-3-DAG" " DAG: 1,2-DIACYLGLYCEROL" "131/132/133/" "1H-NMR: EXCLUSIVELY DEMONSTRATED THAT THE PREPARATION WAS NOT A MIXTURE OF ISOMERS AS REPORTED PREVIOUSLY. (132)" "132/" "WHEAT FLOUR: (131)SPINACH ENVELOPE ISOLATED AT pH 8.5: 0.8 mol% OF THE TOTAL LIPID. SPINACH HOMOGENATES: FORMED IN VITRO AT 4ﾟC AND pH 4.6 FOR 3H UP TO APPROX.20% OF THE TOTAL LIPID.(132/134) CHEMICAL SYNTHESIS: AN ETHER ANALOGUE.(135)" "131/132/134/135/" "BIOSYNTHESIS: ENZYMATIC FORMATION.(136)" "136/" "GL0057" 8.00 "1-O-ACYL-3-[6-O-ACYL-βGALACTOPYRANOSYL]-SN-GLYCEROL" "ACYLMONOGALACTOSYLMONOACYLGLYCEROL" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:137)" " Acyl-6-Galpβ1-3-MAG" " MAG: 1-MONOACYLGLYCEROL" "137/" "SLIGHTLY MORE HYDROPHOBIC THAN MONOGALACTOSYLDIACYLGLYCEROL (137)" "137/" "1H-NMR OF THE TMS OR ACETLY DERIVATIVE IN CDCL3. AN ACYL ESTER CAUSES CONSPICUOUS DOWNFIELD SHIFT OF THE SIGNAL OF THE GEMINAL PROTON. (137)" "EI-MS (137)" "2D-TLC SEPARATION OF TOTAL LIPID. (133) ENZYMATIC EXPERIMENTS WITH RADIOACTIVE SUBSTRATES SHOWED THAT IN VITRO ACYLGALACTOSYLMONOGLUCERIDE CAN ORIGINATE FROM MGMH(137)" "137/" "LEAF HOMOGENATES: (137)" "137/" "GL0058" 8.00 "1,2-DI-O-ALKYL-3-βGUCOPYRANOSYL]-SN-GLYCEROL" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:138)" " Gacpβ1-3-DIALKGRO" " DIALKGRO: 1,2-DI-O-ALKYLGLYCEROL" "138/" "CHEMICAL SYNTHESIS: (138)" "138/" "GL0059" 8.00 "1-O-ACYL-2-βGALACTOPYRANOSYLETHYLENEGLYCOL" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:139)" " Galpβ1-2-MAEG" " MAEG : 1-ACYLETHYLENEGLYCOL" "139/" "EI-MS : TMS-DERIVATIVES GLUCOSYLETHYLENEGLYCOL (COMPARISON WITH GLUCOSYLGLYCEROL) AND ITS ACETATES.(139)" "139/" "RIPENING (IMMATURE) CORN SEED: 1% OF TOTAL LIPID (139) CHEMICAL SYNTHESIS: (139)" "139/" "GL0060" 8.00 "1,2-DI-O-ACYL-3(1)-βGALACTOFURANOSYL-SN-GLYCEROL" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:140)" " Galfβ1-3-DAG" " DAG: 1,2-DIACYLGLYCEROL" "140/" "β'-furanose from(140),[α]/5890 -80ﾟ(141)" "140/141/" "HYDROLYSIS WITH PHOSPHOLIPASE A2, TREATMENT WITH HF, 32P-LABELING FOLLOWED BY 2D-TLC(142),THE OPTICAL ROTATION VALUES GAVE OBVIOUS EVIDENCE FOR A β- FURANOSE FORM. IN ANALOGY TO THAT FROM THE GALACTOSYLDIGLYCERIDES THE GalfGro PREPARATION FROM THE PHOSPHOGALACTOLIPIDS OF B.BIFIDUM IS LIKELY Gal1-3-sm-Gro(180)" "142/180/" "BACTEROIDES SYMBIOSUS: (140) MYCOPLASMA MYCOIDES: 1.3% OF TOTAL LIPID (141) BIFIDOBACTERIUM BIFIDUM VAR. PENNSYLVANICUS: (142)" "140/141/142/" "LABELED WITH 14C-GRO,14C-OLEATE, AND 14C-GLUCOSE (THE DISTRIBUTION OF 14C RADIOACTIVITY AMONG THE LIPID COMPONENTS DESCRIBED).(141) 14C-GLUCOSE MOST HEAVILY LABELED THIS GLYCOLIPID." "141/" "GL0061" 8.00 "1,2-DI-O-ACYL-3(1)-[2',3'-DI-O-ACYL-βGALACTOFURANOSYL]-SN-GLYCEROL" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:143)" " Acyl-O-2-(Acyl-O-3)-Galfβ1-3-DAG" " DAG: 1,2-DIACYLGLYCEROL" "143/" "BIFIDOBACTERIUM BIFIDUM VAR. PENNSYLVANICUS: (143)" "143/" "GL0062" 8.00 "1,2-DI-O-ACYL-3(1)-[3'-O-ACYL-βGALACTOFURANOSYL]-SN-GLYCEROL" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:143)" " Acyl-O-3-Galfβ1-3-DAG" " DAG: 1,2-DIACYLGLYCEROL" "143/" "BIFIDOBACTERIUM BIFIDUM VAR. PENNSYLVANICUS: (143)" "143/" "14C-LABELING USING 14C-UDP-GALACTOSE.(143)" "143/" "GL0063" 8.00 "1,2-DI-O-ACYL-3(1)-αGALACTOFURANOSYL-SN-GLYCEROL" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:144)" " Galfα1-3-DAG" " DAG: 1,2-DIACYLGLYCEROL" "144/" "INTACT GalDAG,GalGro,AND INTACT ACYLATED DIGLUCOSYLCHOLESTEROL.(144)" "144/" "A 2,3'-DI-O-Acyl DERIVATIVE WAS DESCRIBED(144)" "144/" "ACHOLEPLASMA AXANTHUM (144)" "144/" "THE MAJOR COMPONENT OF THIS ORGANISM WAS ACYLATED DIGLUCOSYLCHOLESTEROL, FOLLOWED BY GalDAG AND GLUCOSYLCHOLESTEROL.(144)" "144/" "GL0064" 8.00 "1-O-ALKENYL-2-DI-O-ACYL-3(1)-βGALACTOFURANOSYL-SN-GLYCEROL" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:145)" " Galfβ1-3-AAG" " AAG: 1-ALKYL-2-ACYLGLYCEROL" "145/" "ITS N-VALERYL OR N-BUTYRYL ESTERS WERE DESCRIBED.(145)" "145/" "BUTYRIVIBRIO SP.: (145)" "145/" "GL0065" 8.00 "1,2(2,3)-DI-O-ACYL-3(1)-αGLUCOPYRANOSYL-SN-GLYCEROL" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:146/147/148/149/150/151/152/153/154/155)" " Glcpα1-3(1)DAG" "146/147/148/149/150/151/152/153/154/155/" "(146)" "146/" "EI-MS: ACETATE OF GlcGro.AND Glc2Gro.(152)" "POSITIONAL DISTRIBUTION OF FATTY ACIDS (INCLUDING UNSATURATED AND CYCLOPROPANE ACIDS).(152)" "152/" """PNEUMOCOCCUS: (146/147) DIPLOCOCCUS PNEUMONIAE: 11% OF TOTAL LIPID = 11 mg/g (148) PSEUDOMONAS DIMINUTA: 7.2-10.7% (CA. 31 mg/g) (149)PSEUDOMONAS VESICULARIS: (150) STREPTOCOCCUS LACTIS AND STREPTOCOCCUS HEMOLYTICUS (PYOGENES,TYPE 4): 4.7 AND 5.1" "146/147/148/149/150/151/152/153/154/155/" "GL0066" 8.00 "1,2(2,3)-DI-O-ACYL-3-βGLUCOPYRANOSYL-SN-GLYCEROL" "GLUCOSYLDIGLYCERIDE" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:156/157/158/159/160/161)" " Glcpβ1-3-SN-DAG" " DAG: DIACYLGLYCEROL" "156/157/158/159/160/161/" "(160)" "GC-EI-MS: TMS DERIVATIVE (160)" "160/" "STAPHYLOCOCCUS AUREUS: (156) STAPHYLOCOCCUS LACTIS I3: (157) ALTEROMONAS (PSEUDOMONAS) RUBESCENS: CONTAINS EXTRA TWO FATTY ACIDS (158)MYCOPLASMA NEUROLYTICUM: (159) RICE BRAN: (160) ARTHROBACTER: (161)CHEMICAL SYNTHESIS: 16:0/16:0 SPECIES (162)" "156/157/158/159/160/161/162/" "ON TLC,ACIDIC LIPIDS MAKE ROUNDED, CONICAL SPOT IN NEUTRAL SOLVENT SYSTEMS.COELUTED WITH MONOGLUCURONYL DIACYLGLYCEROL FROM A SILICIC ACID COLUMN BY CHLOROFORM/METHANOL, 95:5 (158)THE LOWER PLANT USUALLY CONTAINS GlcDAG (160)" "158/160/" "GL0067" 8.00 "1,2-DI-O-ACYL-3-βMANNOPYRANOSYL-SN-GLYCEROL" "MANNOSYLDIGLYCERIDE" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:163/164)" " Manpα1-3-SN-DAG" " DAG: DIACYLGLYCEROL" "163/164/" "MYCROCOCCUS LYSODEIKTICUS: (163/164/165) CHEMICAL SYNTHESIS: 16:0/16:0 SPECIES (162)" "163/164/165/162/" "BIOSYNTHESIS (165/166)" "165/166/" "LENNARZ, IN SEARCH OF AN INTERMEDIATE OF GLYCOPROTEIN BIOSYNTHESIS(167/168), DISCOVERED THIS COMPOUND BY RADIOACTIVE LABELING OF THE CELL.(166)" "167/168/166/" "GL0068" 8.00 "1,2(2,3)-DI-O-ACYL-3(1)-α-2-DEOXY-2-ACETAMIDOGLUCOPYRANOSYL-SN-GLYCEROL" "N-ACETYLGLUCOSAMINYLDIGLYCERIDE" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:169)" " GlcpNAcα1-3(1)-SN-DAG" " DAG: DIACYLGLYCEROL" "169/" "EI-MS: (160)" "160/" "STREPTOCOCCUS HEMOLYTICUS: A MINOR COMPONENT (169)" "169/" "GL0069" 8.00 "1,2(2,3)-DI-O-ACYL-3(1)-β-2-DEOXY-2-ACETAMIDOGLUCOPYRANOSYL-SN-GLYCEROL" "N-ACETYLGLUCOSAMINYLDIGLYCERIDE" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:170)" " GlcpNAcβ1-3(1)-SN-DAG" " DAG: DIACYLGLYCEROL" "170/" "BACILLUS MEGATERIUM: 5% OF TOTAL LIPID GLUCOSAMINE (170)" "170/" "THIS GLYCOLIPID COULD BE DISTINGUISHED CHROMATOGRAPHICALLY FROM 2'-(O-β- UCOSAMINYL)PHOSPHATIDYLGLYCEROL AND 3'-(O-β-GLUCOSAMINYL)PHOSPHATIDYL- GLYCEROL IN THE LIPID EXTRACT(170)" "170/" "GL0070" 8.00 "1,2(2,3)-DI-O-ACYL-3(1)-α-D-GLYCERO-D-GLUCOHEPTOPYRANOSYL-SN-GLYCEROL" "HEPTOSYLDIGLYCERIDE" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:150)" " D-Gro-D-Glc-Heppα1-3(1)-SN-DAG" " DAG: DIACYLGLYCEROL" "150/" "PSEUDOMONAS VESICULARIS: (150)" "150/" "THE MAJOR FATTY ACIDS WERE A CIS-OCTADECENOIC ACID AND HEXADECANOIC ACID. C15 AND C17 ACIDS WERE SIGNIFICANT MINOR COMPONENTS.(150)" "150/" "GL0071" 8.00 "1,2-DI-O-ACYL-3-(β-GALACTOSYL-1-2-β-GALACTOSYL)-SN-GLYCEROL" "DIGALACTOSYLDIGLYCERIDE" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF: 143)" " Galβ1-2Galβ1-3-SN-DAG" " DAG: DIACYLGLYCEROL" "143/" "BIFIDOBACTERIUM BIFIDUM: (143)" "143/" "GL0072" 8.00 "1,2-DI-O-ACYL-3-(β-GALACTOFURANOSYL-1-2-(3-O-ACYL)β-GALACTOFURANOSYL)-SN- GLYCEROL" "ACYLDIGALACTOSYLDIGLYCERIDE" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF: 143)" " Galβ1-2(Acyl-3)Galβ1-3-SN-DAG" " DAG: DIACYLGLYCEROL" "143/" "BIFIDOBACTERIUM BIFIDUM: (143)" "143/" "GL0073" 8.00 "1,2-DI-O-ACYL-3-(α-GALACTOPYRANOSYL-1-2-β-GLUCOPYRANOSYL)-SN-GLYCEROL" "GALACTOSYLGLUCOSYLDIGLYCERIDE" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:146/155/171/172/173/174)" " Galpα1-2Glcpα1-3-SN-DAG" " DAG: DIACYLGLYCEROL" "146/155/171/172/173/174/" "SEPARATION OF GLYCOGLYCEROLIPIDS FROM PHOSPHOLIPIDS BY USING KANTO-KAGAKU SILICIC ACID AND CHLOROFORM/ACETONE GRADIENT (172). *FILE(DATA_LC2)のNOTE へつづく→ (173).(174)." "172/173/174/" "PNEUMOCOCCUS I-192: 18.8 mg/g DRY WEIGHT, 34% OF TOTAL LIPID.(171) PNEUMOCOCCUS SP.: (146) DIPLOCOCCUS PNEUMONIAE IR/44: 33%, 33 mg/g DRY CELL. (172)LACTOBACILLUS CASEI: (173). 19.9 mol% (155/174)" "171/146/172/173/155/174/" "SEPARATION OF GLYCOGLYCEROLIPIDS FROM PHOSPHOLIPIDS BY USING KANTO-KAGAKU SILICIC ACID AND CHLOROFORM/ACETONE GRADIENT(172). THE PHOSHOGLYCOLIPID OF LACTOBACILUS CASEI WAS ERRANEOUSLY A SSIGNED ASGLUCOSYLPHOSPHOATIDYLGLYCEROL(173). STEREOCHEMICAL CONF" "172/173/174/" "GL0074" 8.00 "1,2-DI-O-ACYL-3-[α-GALACTOPYRANOSYL-1-2-(6-O-ACYL)-β-GLUCOPYRANOSYL]-SN- GLYCEROL" "GALACTOSYLACYLGLUCOSYLDIGLYCERIDE" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:155)" " Galpα1-2(Acyl-6)Glcpα1-3-SN-DAG" " DAG: DIACYLGLYCEROL" "155/" "LACTOBACILLUS CASEI: 0.7 mol% OF TOTAL LIPID.(155)" "155/" "GL0075" 8.00 "1,2-DI-O-ACYL-3-(α-GLUCOPYRANOSYL-1-2-α-GLUCOPYRANOSYL)-SN-GLYCEROL" "DIGLUCOSYLDIGLYCERIDE,α-KOJIBIOSYLDIGLYCERIDE" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:175)" " Galpα1-2Glcpα1-3-SN-DAG" " DAG: DIACYLGLYCEROL" "175/" "DEACYLATED GlcDAG (=Glc2Gro) FOLLOWS THE LAW OF HOWORTH.(174)" "174/" "1H-NMR OF DEACYLATED Glc2DAG (174)" "174/" "STREPTOCOCCUS LACTIS (SEROGROUP N):(175/176). 7.9 mol% OF TOTAL LIPID.(151)STREPTOCOCCUS FAECIUM (FAECALIS): (154/177) STREPTOCOCCUS PYOGENES (HEMOLYTICUS): 44.3%=57.6 mol%, 66 mg/g DRY CELL(151/178) AHCOLEPLASMA LAIDLAWII: (153)" "175/176/151/154/177/178/153/" "GL0076" 8.00 "1,2-DI-O-ACYL-3-(6-O-ACYL-α-GLUCOPYRANOSYL-1-2-α-GLUCOPYRANOSYL)-SN- GLYCEROL" "ACYLDIGLUCOSYLDIGLYCERIDE,ACYL-α-KOJIBIOSYLDIGLYCERIDE" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:179/180)" " Glcpα1-2(Acyl-6-)Glcpα1-3-SN-DAG" " DAG: DIACYLGLYCEROL" "179/180/" "2D-TLC, HF TREATMENT, HYDROLYSIS WITH α-GALACTOSIDASE.(179)" "179/" "STREPTOCOCCUS LACTIS KIEL 42172: (179) STREPTOCOCCUS LACTIS (SEROGROUP N):A MINOR BUT A COMMON CONSTITUENT OF ALL 7 STRAINS OF GROUP N STREPTOCOCCI (180)" "179/180/" "DETERMINATION OF THE POSITION OF ACYL GROUP BY TWO-STEP METHYLATION METHOD.(180)" "180/" "GL0077" 8.00 "1,2-DI-O-ACYL-3-(β-GLUCOPYRANOSYL-1-6-β-GLUCOPYRANOSYL)-SN-GLYCEROL" "DIGLUCOSYLDIGLYCERIDE, β-GENTIOBIOSYLDIGLYCERIDE" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:181)" " Glcpβ1-6Glcpβ1-3-SN-DAG" " DAG: DIACYLGLYCEROL" "181/" "PRECISE DETERMINATION OF DEACYLATED GLYCOLIPIDS AND EXTENSIVE DISCUSSIONS ON THE MOLAR ROTATIONS.(183)" "183/" "1H-NMR OF PERMETHYLATED GLYCOLIPIDS.(183)" "DiPtdGro AND PtdA COULD BE NEATLY SEPARATED FROM OTHER LIPIDS.(183) STEREOCHEMICAL CONFIGURATION OF Gro MOIETY AND THE OCATION OF GroP.(174)" "183/174/" "STAPHYLOCOCCUS AUREUS: (156/174/181) STAPHYLOCOCCUS LACTIS I3: O.7 mg/g DRY CELL=3% OF TOTAL LIPID (138/157/175)STAPHYLOCOCCUS LACTIS 7944: 1-2% OF TOTAL LIPID (182)STAPHYLOCOCCUS EPIDERMIDIS: (183) BACILLUS SUBTILIS: (175/138) BACILLUS CEREUS: (184)ACI" "156/174/181/138/157/175/182/183/184/185/159/" "GL0078" 8.00 "1,2-DI-O-ACYL-3-(α-MANNOPYRANOSYL-1-3-α-MANNOPYRANOSYL)-SN-GLYCEROL" "DIMANNOSYLDIGLYCERIDE" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:164)" " Manpα1-3Manpα1-3-SN-DAG" " DAG: DIACYLGLYCEROL" "164/" "MYCROCOCCUS LUTEUS (LYSODEIKTICUS): ISOLATION (163) MYCROCOCCUS LUTEUS: STRUCTURE AND METABOLISM. 7-15% OF TOTAL LIPID OR 0.75-1.5 mg/g (164)ARTHROBACTER: (161) MICROBACTERIUM LACTICUM: 46% OF TOTAL LIPID, OR 4.9% OF DRY CELL.(186)" "163/164/161/186/" "GL0079" 8.00 "1,2-DI-O-ACYL-3-(α-GALACTOPYRANOSYL-1-6-α-GALACTOPYRANOSYL-1-6-β-GALACTOPYRANOSYL)-SN-GLYCEROL" "TRIGALACTOSYLDIGLYCERIDE" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:187)" " Galpα1-6Galpα1-6Galpβ1-3-SN-DAG" " DAG: DIACYLGLYCEROL" "187/" "EI-MS OF ACETATE (191)" "FATTY ACID MOLECULAR SPECIES (191)" "191/" "POTATO TUBER: ISOLATION AND STRUCTURE. 1% OF TOTAL LIPID, OR 10μg/g TUBER (187) APPLE PULP: (188/190)RICE BRAN: (160) SPINACH ENVELOPE: 1.5% OF TOTAL LIPID (189), 5.2 mol% OF TOTAL LIPID (191) CHEMICAL SYNTHESIS: (192/193)" "187/188/190/160/189/191/192/193/" "GL0080" 8.00 "1,2-DI-O-ACYL-3-(β-GALACTOPYRANOSYL-1-2-β-GALACTOPYRANOSYL-1-2-β-GALACTOPYRANOSYL)-SN-GLYCEROL" "TRIGALACTOSYLDIGLYCERIDE" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:143)" " Galpβ1-2Galpβ1-2Galpβ1-3-SN-DAG" " DAG: DIACYLGLYCEROL" "143/" "BIFIDOBACTERIUM BIFIDUM:(143)" "143/" "GL0081" 8.00 "1,2-DI-O-ACYL-3-(α-GLUCOPYRANOSYL-1-2-α-GLUCOPYRANOSYL-1-2-α- GLUCOPYRANOSYL)-SN-GLYCEROL" "TRIGLUCOSYLDIGLYCERIDE,α-KOJITRIOSYLDIGLYCERIDE" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:151/178/194)" " Glcpα1-2Glcpα1-2Glcpα1-3-SN-DAG" " DAG: DIACYLGLYCEROL" "151/178/194/" "DEACYLATED GlcDAG (=Glc2Gro) FOLLOWS THE LAW OF HOWORTH.(174)" "174/" "1H-NMR OF DEACYLATED Glc2Gro.(174)" "174/" "STREPTOCOCCUS HEMOLYTICUS: 0.9% OR 6.6 mol% OF TOTAL LIPID (151/178) STREPTOCOCCUS FAECIUM: (194)" "151/178/194/" "GL0082" 8.00 "1,2-DI-O-ACYL-3-[α-GLUCOPYRANOSYL-1-2-α-GLUCOPYRANOSYL-1-2-(6-O-ACYL-α-GLUCOPYRANOSYL)]-SN-GLYCEROL" "ACYLTRIGLUCOSYLDIGLYCERIDE,ACYL-α-KOJITRIOSYLDIGLYCERIDE" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:155)" " Glcpα1-2Glcpα1-2(Acyl-6)Glcpα1-3-SN-DAG" " DAG: DIACYLGLYCEROL" "155/" "LACTOBACILLUS CASEI: 3% OF TOTAL LIPID (155)" "155/" "GL0083" 8.00 "1,2-DI-O-ACYL-3-(β-GLUCOPYRANOSYL-1-6-α-GALACTOPYRANODYL-1-2-α-GLUCOPYRANOSYL)-SN-GLYCEROL" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:155)" " Glcpβ1-6Galpα1-2Glcpα1-3-SN-DAG" " DAG: DIACYLGLYCEROL" "155/" "LACTOBACILLUS CASEI: LESS THAN 17% OF TOTAL LIPID (173) LACTOBACILLUS CASEI: THE FINAL STRUCTURE. 26.2 mol% OF TOTAL LIPID (155)" "173/155/" "GL0084" 8.00 "1,2-DI-O-ACYL-3-(β-GLUCOPYRANOSYL-1-6-α-GALACTOPYRANOSYL-1-2-α-(6-O-ACYL)GLUCOPYRANOSYL))-SN-GLYCEROL" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:155)" " Glcpβ1-6Galpα1-2(Acyl-6-)Glcpα1-3-SN-DAG" " DAG: DIACYLGLYCEROL" "155/" "LACTOBACILLUS CASEI: LESS THAN 17% OF TOTAL LIPID (155)" "155/" "ALSO OCCURS AS THE COMPONENT OF LIPOTEICHOIC ACIDS. (155)" "155/" "GL0085" 8.00 "1,2-DI-O-ACYL-3-(β-GLUCOPYRANOSYL-1-6-β-GLUCOPYRANOSYL-1-6-β-GLUCOPYRANOSYL)-SN-GLYCEROL" "TRIGLUCOSYLDIGLYCERIDE,α-GENTIOTRIOSYLDIGLYCERIDE" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:195)" " Glcpβ1-6Glcpβ1-6Glcpβ1-3-SN-DAG" " DAG: DIACYLGLYCEROL" "195/" "LACTOBACILLUS CASEI: 3.2 mol% OF TOTAL LIPID (195)" "195/" "GL0086" 8.00 "1,2-DI-O-ACYL-3-(β-GLUCOPYRANOSYL-1-6-β-GLUCOPYRANOSYL-1-6-α-GALACTO-PYRANOSYL-1-2-β-GLUCOPYRANOSYL)-SN-GLYCEROL" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:155/196)" " Glcpβ1-6Glcpβ1-6Galpα1-2-β-Glcp1-3-SN-DAG" " DAG: DIACYLGLYCEROL" "155/196/" "EI-MS OF ACETATE (191)" "FATTY ACID MOLECULAR SPECIES (191)" "191/" "LACTOBACILLUS CASEI: 5.5 mol% OF TOTAL LIPID (155/196)" "155/196/" "GL008v7" 8.00 "1,2(2,3)-DI-O-ACYL-3(1)-(α-GALACTOPYRANOSYL-1-6-α-GALACTOPYRANOSYL-1-6-α-GALACTOPYRANOSYL-1-6-β-GALACTOPYRANOSYL)-SN-GLYCEROL" "TETRAGALACTOSYLDIGLYCERIDE" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:197)" " Galpα1-6Galpα1-6Galpα1-6-β-Galp1-3(1)-SN-DAG" " DAG: DIACYLGLYCEROL" "197/" "GC-EI-MS OF TMS DERIVATIVE.(160)" "160/" "SPINACH CHLOROPLASTS: ABOUT 1% OF GALACTOSYLGLYCOGLYCEROLIPIDS. RELATIVE AMOUNT (MOLAR RATIO) OF GALACTOLIPIDS WAS MONO-:DI-: TRI-:TETRA-=60:30:5:1 (197)RICE BRAN: 2.3% OF TOTAL IPID(160) CASSAVA TUBERS (TAPIOCA): 7.3%(198) APINACH ENVELOPE: 2.1 mol% OF" "197/160/198/191/133/" "SYNTHESIZED WITH CHLOROPLAST ENZYMES USING UDP-GALACTOSE AS A GALACTOSEDONOR.(197) THEEXTRACTABLE LIPIDS OF CASSAVA TUBER FLOUR COMPRIZED ABOUT HALF THETOTAL FLOUR LIPID (2.5%) AND CONSISTED CHIEFLY OF GalDAGs. THESE INCLUDED TETRA-GalDAG (7.3% OF TOTAL" "197/198/191/" "GL0088" 8.00 "1-O-HEXADECYL-2-O-HEXADECANOYL-3-(α-RHAMNOPYRANOSYL-1-4-β-GALACTOPYRANO- SYL-1-4-β-GALACTOPYRANOSYL-1-4-β-GALACTOPYRANOSYL)-SN-GLYCEROL" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:199)" " Rhampα1-4Galpβ1-4Galpβ1-4Glcp-β1-2-SN-AAG" " AAG: ALKYLACYLGLYCEROL" "199/" "MUNG BEAN (PHASEOLUS MUNGO) SPROUT: 7-DAY MUNG BEAN, 0.2% OF TOTAL LIPID. (199)" "199/" "GL0089" 8.00 "1,2(2,3)-DI-O-ACYL-3(1)-(α-GALACTOPYRANOSYL-1-2-α-GALACTOPYRANOSYL-1-3-β-D-GLYCERO-D-ANNOHEPTOPYRANOSYL-1-3-α-GLUCOPYRANOSYL-1-2-α-GLUCOPYRANOSYL-1-2-α-GLUCOPYRANOSYL)-SN-GLYCEROL" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:200)" " Galpα1-2Galpα1-3-D-Gro-D-Mannoheppβ1-3Glcpα1-2Glcpα1-3(1)-SN-DAG" " DAG: DIACYLGLYCEROL" "200/" "ACHOLEPLASMA MODICUM: (200)" "200/" "GL0090" 8.00 "1,2-DI-O-ACYL-3-αGLUCURONOPYRANOSYL-GLYCEROL" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:149/150/201)" " GlcpUα1-3-SN-DAG" " DAG: DIACYLGLYCEROL" "149/150/201/" "PSEUDOMONAS DIMINUTA: 3.5% OF TOTAL LIPID OR 15 mg/g.(149)METABOLISM.(201)PSEUDOMONAS VESICULARIS: (150)" "149/201/150/" "GL0091" 8.00 "1,2-DI-O-ACYL-3-βGLUCURONOPYRANOSYL-GLYCEROL" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:158/202)" " GlcpUβ1-3-SN-DAG" " DAG: DIACYLGLYCEROL" "158/202/" "ALTEROMONAS (PSEUDOMONAS) RUBESCENS: 3.0% OF TOTAL LIPID.(158) METABOLISM AND THE RELATION WITH GROWTH PHASE.(202)PSEUDOMONAS VESICULARIS: (150)" "158/202/150/" "GL0092" 8.00 "1,2-DI-O-ACYL-3-(βGLUCOPYRANOSYL-1-4-αGLUCURONOPYRANOSYL)-SN-GLYCEROL" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:149/150)" " Glcpβ1-4GlcpUα1-3-SN-DAG" " DAG: DIACYLGLYCEROL" "149/150/" "PSEUDOMONAS DIMINUTA: 4.1% OF TOTAL LIPID.(149) PSEUDOMONAS VESICULARIS: (150)" "149/150/" "GL0093" 8.00 "1,2-DI-O-ACYL-3-(αGLUCOPYRANOSYL-1-4-αGALACTURONOPYRANOSYL)-SN-GLYCEROL" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:203)" " Glcpα1-4GlcpUα1-3(1)-SN-DAG" " DAG: DIACYLGLYCEROL" "203/" "STREPTOMYCES LA 7071: 6% OF TOTAL LIPID. ACYLATED AT POSITION-2 OR -3 OF GalUp (203)" "203/" "GL0094" 8.00 "1,2(2,3)-DI-O-ACYL-3(1)-(αN-ACETYLNEURAMINOSYL-1-9-αN-ACETYLNEUAMINOSYL-2)-SN-PHOSPHATIDATE" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:204)" " NeuAcα2-9NeuAcα2-SN-PTD" " PTD: PHOSPHATIC ACID" "204/" "C-2 CARBOXYL OF NeuAc IS GLYCOSIDICALLY BOUND TO THE PHOSPHATEMONOESTER OF PHOSPHATIDIC ACID.( )" "MENINGOCOCCUS AND E. COLI K92 (204)" "204/" "THE PRESENCE OF THE HYDROPHOBIC END CAUSES THE POLYSACCHARIDES TO AGGREGATE IN A MICELLAR FORM AND MAY BE THE ENTITY BY WHICH THE POLYSACCHARIDE REMAINS ATTACHED TO THE OUTER MEMBRANE OF THE BACTERIUM GIVING RISE TO THE STRU-CTURE RECOGNIZED AS A CAPSULE." "204/" "GL0095" 8.00 "1,2(2,3)-DI-O-ACYL-3(1)-(αN-ACETYLNEURAMINOSYL-1-9-αN-ACETYLNEUAMINOSYL-2)-SN-DIACYLGLYCEROL" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:205)" " NeuAcα2-9NeuAcα2-3-SN-DAG" " DAG: DIACYLGLYCEROL" "205/" "CHEMICAL SYNTHESIS(205)" "205/" "GL0096" 8.00 "1,2(2,3)-DI-O-ACYL-3(1)-(βN-ACETYLNEURAMINOSYL-1-9-αN-ACETYLNEUAMINOSYL-2)-SN-DIACYLGLYCEROL" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:205)" " NeuAcα2-9NeuAcα2-3-SN-DAG" " DAG: DIACYLGLYCEROL" "205/" "CHEMICAL SYNTHESIS(205)" "205/" "GL0097" 8.00 "β-MANNOSYL(1-4)β-GLUCOSYL(1-1)CERAMIDE" "13" "C46H87O13N" 46.00 87.00 13.00 1.00 0.00 0.00 861.00 "Manβ1-4Glcβ1-1Cer (REF:022)" "022/" "C-M(2:1)に可溶" "セタシジミ(022)，キンバエ(023)，イケチョウガイ(024)，ハマグリ(025)" "022/023/024/025/" "GL0098" 8.00 "α-MANNOSYL(1-4)β-MANNOSYL(1-4)β-GLUCOSYL(1-1)CERAMIDE" "13" "C52H97O18N" 52.00 97.00 18.00 1.00 0.00 0.00 1023.00 "Manα1-4Manβ1-4Glcβ1-1Cer (REF:022)" "022/" "C-M(2:1)に可溶" "セタシジミ(022)" "022/" "GL0099" 8.00 "2-O-ACYL-β-D-GLUCOPYRANOSYLCERAMIDE" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " Glcβ1-1Cer (REF:004)" " 2" " |" " Acyl" "004/" "1738cm-1 ｶﾙﾎﾞﾆﾙｴｽﾃﾙ(004) 2922, 2852cm-1 -CH stretchingの吸収大(004)" "004/" "スケトウダラ脳(004)" "004/" "TLC(004)、長鎖塩基と脂肪酸組成(004)" "004/" "GL0100" 8.00 "3-O-ACYL-β-D-GLUCOPYRANOSYLCERAMIDE" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " Glcβ1-1Cer (REF:004)" " 3" " |" " Acyl" "004/" "1738cm-1 ｶﾙﾎﾞﾆﾙｴｽﾃﾙ(004) 2922,2852cm-1 -CH stretchingの吸収大(004)" "004/" "スケトウダラ脳(004)、ブタとヒト表皮(016)" "004/016/" "脂肪酸と長鎖塩基組成(004)" "004/" "GL0101" 8.00 "6-O-ACYL-β-D-GLUCOPYRANOSYLCERAMIDE" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " Glcβ1-1Cer (REF:004)" " 6" " |" " Acyl" "004/" "1738cm-1 ｶﾙﾎﾞﾆﾙｴｽﾃﾙ(004) 2922, 2852cm-1 -CH stretchingの吸収大(004)" "004/" "スケトウダラ脳(004)、GAUCHER病患者脾(015)" "015/" "脂肪酸と長鎖塩基組成(004)" "004/" "GL0102" 8.00 "2-O-ACYL-β-D-GALACTOPYRANOSYLCERAMIDE" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " Galβ1-1Cer (REF:004)" " 2" " |" " Acyl" "004/" "1730cm-1 ｶﾙﾎﾞﾆﾙｴｽﾃﾙ (004)" "004/" "スケトウダラ脳(004)、ヒトとウシ脳(013)、クジラ脳(014)" "004/013/014/" "分子種間のTLC移動度の比較(004)、脂肪酸と長鎖塩基組成(004)" "004/" "GL0103" 8.00 "3-O-ACYL-β-D-GALACTOPYRANOSYLCERAMIDE" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " Galβ1-1Cer (REF:002)" " 3" " |" " Acyl" "002/" "［α］D IN CHCl3 FrII.=-5.0, FrIII.=+3.0, FrIV.=+0.6 (002)" "1730cm-1 ｶﾙﾎﾞﾆﾙｴｽﾃﾙ, 1640cm-1 酸ｱﾐﾄﾞ(002/004)" "002/004/" "ウシ脳(001/002/003)、ウシ脳スフィンゴリピド画分の1.1%(002)、ヒト脳(011/013)，スケトウダラ脳(004)、ブタ胃(012)、クジラ脳(014)" "011/002/003/013/004/012/014/" "脂肪酸と長鎖塩基組成(002/003/004/011)、TLC(001/002/003/004/011)" "002/003/004/011/001/" "GL0104" 8.00 "4-O-ACYL-β-D-GALACTOPYRANOSYLCERAMIDE" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " Galβ1-1Cer (REF:004)" " 4" " |" " Acyl" "004/" "1738cm-1 ｶﾙﾎﾞﾆﾙｴｽﾃﾙ(004) 2922,2852cm-1 -CH Stretchingの吸収大(004)" "004/" "スケトウダラ脳(003/004)、 ぶた胃(012)、ヒトとウシ脳(013)、クジラ脳(014)" "003/004/012/013/014/" "脂肪酸と長鎖塩基組成(004)、 TLC(003/004)" "004/003/" "GL0105" 8.00 "6-O-ACYL-β-D-GALACTOPYRANOSYLCERAMIDE" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " Galβ1-1Cer (REF:002)" " 6" " |" " Acyl" "002/" "［α］D IN CHCl3 FrII.=-5.0, FrIII.=+3.0, FrIV.=+0.6 (002)" "1730cm-1 ｶﾙﾎﾞﾆﾙｴｽﾃﾙ，1640,1530cm-1 酸ｱﾐﾄﾞ(001/002/004)" "001/002/004/" "ウシ脳(001/002/008/013)、ウシ脳スフィンゴリピド画分の1.1%(002)、スケトウダラとマダラ脳(003/004)、スケトウダラ脳神経組織分布(003)、スケトウダラ脳分子種(004)、ヒト脳(009/011/013)、ブタ脳(010/017)、ブタ胃(012)。クジラ脳(014)" "001/002/008/013/003/004/009/011/010/017/012/014/" "脂肪酸組成（直鎖酸とｵｷｼ酸）の組み合わせで４画分(001/002) Folch分配(005)、 TLC(001/002/010)、脂肪酸と長鎖塩基組成(002/004/010)、 Hakomoriのﾒﾁﾙ化法(006)とKuhnのﾒﾁﾙ化法(007)の比較(002)" "001/002/005/010/004/006/002/" "GL0106" 8.00 "1,2-di-O-ACYL-3-β(2'-O-ACYL-D-GALACTOPYRANOSYL)-sn-GLYCEROL" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " Galβ1-3DAG (REF:004)" " 2" " |" " Acyl" "004/" "1738cm-1 ｶﾙﾎﾞﾆﾙｴｽﾃﾙの存在、 1648,1541cm-1 酸ｱﾐﾄﾞの欠如(004) 2922,2852cm-1 -CH CTRETCHINGの吸収大(004)" "004/" "スケトウダラ脳(003/004)、マダラ脳(003)、コイ脳(003)、神経組織分布(003)" "003/004/" "脂肪酸組成(003/004)" "003/004/" "GL0107" 8.00 "1,2-di-O-ACYL-3-β(6-O-ACYL-D-GALACTOPYRANOSYL)-sn-GLYCEROL" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " Galβ1-3DAG (REF:004" " 6" " |" " Acyl" "004/" "1738cm-1 ｶﾙﾎﾞﾆﾙｴｽﾃﾙの存在、1648,1541cm-1 酸ｱﾐﾄﾞの欠如(004) 2922,2852cm-1 -CH STRETCHINGの吸収大(004)" "004/" "スケトウダラ脳(003/004)、マダラ脳(003)、コイ脳(003)、神経組織分布(003)、ホウレンソウホモジネート(018/020)、ホーレンソウホモジネートによる酵素的生合成(019/021/022)、コムギ粉(023)、ホウレンソウクロロプラストの生合成能とpHとの関係(024/025)" "003/004/018/020/019/021/022/023/024/025/" "脂肪酸組成(003/004)" "003/004/" "GL0108" 8.00 "GALACTOSYLβ1-4(FUCOSYLα1-3)GULCOSYLβ1-3GALACTOSYLβ1-1CERAMIDE" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " Galβ1-4Glcβ1-3Galβ1-1Cer (REF:027)" " 4" " |" " Fucα1" "027/" "1H 1D-NMR, TOCSY, ROESY (027)" "INTACT FAB-MS (027)" "027/" "マンソン裂頭条虫(027)" "027/" "TLC(027) 長鎖塩基と脂肪酸組成(027)" "027/" "GL0109" 8.00 "N-ACETYLNEURAMINYLα2-3GALACTOSYLβ1-3(N-ACETYLNEURAMINYLα2-6)N-ACETYL -GALACTOSAMINYLβ1-4(N-ACETYLNERAMINYLα2-3)GALACTOSYLβ1-4GLUCOSYLCERAMIDE or, U3,V6,W3-α-TRI-N-ACETYLNEURAMINYLGANGLIOTETRAOSYLCERAMIDE" "II3,III6,IV3α-GgOSe4Cer" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " Galβ1-3GalNAcβ1-4Galβ1-4Glcβ1-1Cer (REF:026)" " 3 6 3" " | | |" " 2 2 2" " NeuAcα NeuAcα NeuAcα" "026/" "1D 1H-NMR (026/028) HOHHAHA (028)" "INTACT FAB-MS (026/028)" "026/028/" "サメ脳(026)、ウシ脳(028)" "026/028/" "抗コリン作動ニュ−ロン特異的抗体と反応(028)" "028/" "TLC(026/028) 脂肪酸と長鎖塩基組成(026)" "028/026/" "GL0110" 8.00 "β-2-ACETAMIDE-2-DEOXY-GLUCOSYL(1-2)α-MANNOSYL(1-3)β-MANNOSYL(1-4)β-GLUCOSYL(1-1)CERAMIDE" "11" "C62H114O23N2" 62.00 114.00 23.00 2.00 0.00 0.00 1254.00 "GlcNAcβ1-2Manα1-3Manβ1-4GLCβ1-1Cer (REF:026)" "026/" "C-M(1:1)に可溶" "イケチョウガイ（026)，ハマグリ(025)" "026/025/" "GL0111" 8.00 "β-2-ACETAMIDE-2-DEOXY-GLUCOSYL(1-2)α-MANNOSYL(1-3)[β-XYLOSYL(1-2)]β-MANNOSYL(1-4)β-GLUCOSYL(1-1)CERAMIDE" "11" "C67H122O27N2" 67.00 122.00 27.00 2.00 0.00 0.00 1386.00 "GlcNAcβ1-2Manα1-3Manβ1-4Glcβ1-1Cer (REF:027)" " 2" " |" " Xylβ1" "027/" "C-M(1:1)に可溶" "イケチョウガイ（027)，ハマグリ(025)" "027/025/" "GL0112" 8.00 "β-4-O-METHYLGALACTOSYL(1-3)β-2-ACETAMIDE-2-DEOXY-GALACTOSYL(1-3)α-FUCOSYL(1-4)β-2-ACETAMIDE-2-DEOXY-GLUCOSYL(1-2)α-MANNOSYL(1-3)[α-XYLOSYL(1-2)][2'-AMINOETHYLPHOSPHORYL(-6)]β-MANNOSYL(1-4)β-GLUCOSYL(1-1)CERAMIDE" "11" "C90H163O45N4P" 90.00 163.00 45.00 4.00 1.00 0.00 2049.00 " O (REF:028)" " (+) ‖" " H3N-CH2-CH2-P-O" " | |" " HO 6" " Galβ1-4GalNAcβ1-3Fucα1-4GlcNAcβ1-2Manα1-3Manβ1-4Glcβ1-1Cer" " 4 2" " | |" " Me Xylα1" "028/" "C-M-W(6:4:1)に可溶" "セタシジミ(028)" "028/" "GL0113" 8.00 "α-MANNOSYL(1-3)[β-XYLOSYL(1-2)]β-MANNOSYL(1-4)β-GLUCOSYL(1-1)CERAMIDE" "11" "C51H109O22N" 51.00 109.00 22.00 1.00 0.00 0.00 1087.00 "Manα1-3Manβ1-4Glcβ1-1Cer (REF:029)" " 2" " |" " Xylβ1" "029/" "C-M(1:1)に可溶" "イケチョウガイ(029)" "029/" "GL0114" 8.00 "α-3-O-METHYLFUCOSYL(1-2)β-3-O-METHYLXYLOSYL(1-4)[α-3-O-METHYL-2-ACETAMIDE-2-DEOXY-GALACTOSYL(1-3)]α-FUCOSYL(1-4)β-2-ACETAMIDE-2-DEOXY-GLUCOSYL(1-2)α-MANNOSYL(1-3)[β-XYLOSYL(1-2)]β-MANNOSYL(1-4)β-GLUCOSYL(1-1)CERAMIDE" "11" "C95H169O44N" 95.00 169.00 44.00 3.00 0.00 0.00 2055.00 " Fucα1-2Xylβ1-4Fucα1-4GlcNAcβ1-2Manα1-3Manβ1-4Glcβ1-1Cer" " 3 3 3 2" " | | | | (REF:030)" " Me Me GalNAcα1 Xylβ1" " 3" " |" " Me" "030/" "C-M(1:1)に可溶(030)" "030/" "PROTEN NMRスペクトルでアノマー配置を決定(030)" "030/" "イケチョウガイ(030)，ハマグリ(025)" "030/025/" "GL0115" 8.00 "β-4-O-METHYLGLUCURONYL(1-4)[α-3-O-METHYL-2-ACETAMIDE-2-DEOXY-GALACTOSYL(1-3)]α-FUCOSYL(1-4)β-2-ACETAMIDE-2-DEOXY-GLUCOSYL(1-2)α-MANNOSYL(1-3)[ βXYLOYL(1-2)]β-MANNOSYL(1-4)β-GLUCOSYL(1-1)CERAMIDE" "11" "C89H157O42N3" 89.00 157.00 42.00 3.00 0.00 0.00 1939.00 " GlcAβ1-4Fucα1-4GlcNAcβ1-2Manα1-3Manβ1-4Glcβ1-1Cer (REF:031)" " | 3 2" " Me | |" " GalNAcα1 Xylβ1" " 3" " |" " Me" "031/" "C-M-W(6:4:1)，水に可溶" "PROTON NMRでアノマー配置を決定(031)" "031/" "イケチョウガイ(031)，ハマグリ(025)" "031/025/" "イケチョウガイ精子に局在していることを免疫化学的に検出したので，卵の認識に 関与していることを予想した(032)" "032/" "GL0116" 8.00 "β-4-METHYLGALACTOSYL(1-3)β-2-ACETAMIDE-2-DEOXY-GALACTOSYL(1-3)αFUCOSYL(1-4)β-2-ACETAMIDE-2-DEOXY-GLUCOSYL(1-2)α-MANNOSYL(1-3)[α-XYLOSYL(1-2) βMANNOSYL(1-4)β-GLUCOSYL(1-1)CERAMIDE" "11" "C86H153O41N3" 86.00 153.00 41.00 3.00 0.00 0.00 1883.00 " Galβ1-3GalNAcβ1-3Fucα1-4GlcNAcβ1-2Manα1-3Manβ1-4Glcβ1-1Cer" " 4 2" " | | (REF:033)" " Me Xylα1" "033/" "C-M-W(6:4:1)，水に可溶" "PROTON NMRでアノマー配置を決定" "セタシジミ(033)" "033/" "GL0117" 8.00 "β-MANNOSYL(1-2)β-MANNOSYL(1-1)CERAMIDE" "13" "C46H87O13N" 46.00 87.00 13.00 1.00 0.00 0.00 861.00 " Manβ1-2Manβ1-1Cer (REF:024)" "024/" "C-M(2:1)に可溶" "イケチョウガイ(024)" "024/" "GL0118" 8.00 "α-MANNOSYL(1-3)β-MANNOSYL(1-2)β-MANNOSYL(1-1)CERAMIDE" "13" "C54H101O18N" 54.00 101.00 18.00 1.00 0.00 0.00 1051.00 " Manα1-3Manβ1-2Manβ1-1Cer (REF:024)" "024/" "C-M(2:1)に可溶" "イケチョウガイ(024)" "024/" "GL0119" 8.00 "α-MANNOSYL(1-3)β-MANNOSYL(1-4)β-GLUCOSYL(1-1)CERAMIDE" "11" "C54H101O18N" 54.00 101.00 18.00 1.00 0.00 0.00 1051.00 " Manα1-3Manβ1-4Glcβ1-1Cer (REF:024)" "024/" "C-M(2:1)に可溶" "イケチョウガイ(029/024)，ハマグリ(025)" "029/024/025/" "GL0120" 8.00 "α-MANNOSYL(1-3)[β-GALACTOSYL(1-2)]β-MANNOSYL(1-4)β-GLUCOSYL(1-1)CERAMIDE" "11" "C60H111O23N" 60.00 111.00 23.00 1.00 0.00 0.00 1213.00 " Manα1-3Manβ1-4Glcβ1-1Cer (REF:035)" " 2" " |" " Galβ1" "035/" "C-M(1:1)に可溶，C-M-W(6:4:1)に昜溶" "イケチョウガイ卵(035)" "035/" "GL0121" 8.00 "α-GALACTOSYL(1-3)β-MANNOSYL(1-4)β-GLUCOSYL(1-1)CERAMIDE" "13" "C53H97O18N" 53.00 97.00 18.00 1.00 0.00 0.00 1035.00 " Galα1-3Manβ1-4Glcβ1-1Cer (REF:025)" "025/" "C-M(2:1)に可溶" "ハマグリ(025)" "025/" "GL0122" 8.00 "ARABINOSYL(1-6)β-GALACTOSYL[β-GALACTOSYL(1-8)]N-GLYCOLYLNEURAMINYL(2-3) β-GALACTOSYL(1-4)β-GLUCOSYL(1-1)CERAMIDE" "13" "C79H144O38N2" 79.00 144.00 38.00 2.00 0.00 0.00 1728.00 " Ara(1-6)Galβ1-4NeuGc2-3Galβ1-4Glcβ1-1Cer (REF:036)" " 8" " |" " Galβ1" "036/" "C-M-W(30:60:8)に可溶，Folch分配で上層部にくる" "1640,1540cm-1(AMIDE LINKAGE), 1000-1100cm-1(ALCOHOLIC OH)(036)" "036/" "イトマキヒトデ(036)" "036/" "GL0123" 8.00 "β-ARABINOSYL(1-6)β-GALACTOSYL(1-4)8-O-METHYL-N-GLYCOLYLNEURAMINYL(2-3)β-GALACTOSYL(1-4)β-GLUCOSYL(1-1)CERAMIDE" "13" "C74H136O33N2" 74.00 136.00 33.00 2.00 0.00 0.00 1580.00 " Araβ1-6Galβ1-4NeuGc2-3Galβ1-4Glcβ1-1Cer (REF:037)" " 8" " |" " Me" "037/" "C-M-W(30:60:8)に可溶，Folch分配で上層にくる" "036/" "イトマキヒトデ(037)" "037/" "GL0124" 8.00 "β-ARABINOSYL(1-6)β-GALACTOSYL(1-4)N-GLYCOLYLNEURAMINYL(2-3)β-GALACTOSYL (1-4)β-GLUCOSYL(1-1)CERAMIDE" "13" "C73H134O33N2" 73.00 134.00 33.00 2.00 0.00 0.00 1566.00 " Araβ1-6Galβ1-4NeuGc2-3Galβ1-4Glcβ1-1Cer (REF:037)" "037/" "C-M-W(30:60:8)に可溶，Folch分配で上層部にくる" "036/" "イトマキヒトデ(037)" "037/" "GL0125" 8.00 "β-2-ACETAMIDE-2-DEOXY-GLUCOSYL(1-3)β-MANNOSYL(1-4)β-GLUCOSYL(1-1)CERAMIDE" "10" "C54H100O18N2" 54.00 100.00 18.00 2.00 0.00 0.00 1064.00 " GlcNAcβ1-3Manβ1-4Glcβ1-1Cer (REF:023)" "023/" "C-M(1:1)に可溶" "1540,1645cm-1(AMIDE LINKAGE), 3300cm-1(FREE OH) (023)" "023/" "キンバエ(023)" "023/" "GL0126" 8.00 "β-2-ACETAMIDE-2-DEOXY-GALACTOSYL(1-4)β-2-ACETAMIDE-2-DEOXY-GLUCOSYL(1-3) β-MANNOSYL(1-4)β-GLUCOSYL(1-1)CERAMIDE" "10" "C62H113O23N3" 62.00 113.00 23.00 3.00 0.00 0.00 1267.00 " GalNAcβ1-4GlcNAcβ1-3Manβ1-4Glcβ1-1Cer (REF:023)" "023/" "C-M(1:1)に可溶" "1540,1645cm-1(AMIDE LINKAGE), 3300cm-1(FREE OH) (023)" "023/" "キンバエ(023)" "023/" "GL0127" 8.00 "α-2-ACETAMIDE-2-DEOXY-GALACTOSYL(1-4)β-2-ACETAMIDE-2-DEOXY-GALACTOSYL(1-4)β-2-ACETAMIDE-2-DEOXY-GLUCOSYL(1-3)β-MANNOSYL(1-4)β-GLUCOSYL(1-1) CERAMIDE" "10" "C70H126O28N4" 70.00 126.00 28.00 4.00 0.00 0.00 1470.00 " GalNAcα1-4GalNAcβ1-4GlcNAcβ1-3Manβ1-4Glcβ1-1Cer (REF:038)" "038/" "C-M(1:1)に可溶" "キンバエ(038)" "038/" "GL0128" 8.00 "N-ACETYLGALACTOSAMINYLβ1-4(9-O-ACETYL-N-ACETYLNEURAMINYLα2-8N-ACETYLNEURAMINYLα2-8N-ACETYLNEURAMINYLα2-3)GALACTOSYLβ1-4GLUCOSYLCERAMIDE" "II3Ac9NeuAcα2-8NeuAcα2-8NeuAcα-GgOse3Cer" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " GalNAcβ1-4Galβ1-4Glcβ1-1Cer (REF:030)" " 3" " |" " NeuAcα2" " 8" " |" " NeuAcα2" " 8" " |" "Ac-9NeuAc2" "030/" "FAB-MS (030)" "030/" "タラ脳(030)" "030/" "ＴＬＣパターン(030)" "030/" "GL0129" 8.00 "N-ACETYLNEURAMINYLα2-3GALACTOSYLβ1-3(FUCOSYLα1-4)N-ACETYLGLUCOSAMINYLβ1-3(GALACTOSYLβ1-4N-ACETYLGLUCOSAMINYLβ1-6)GALACTOSYLβ1-4GLUCOSYLCERAMIDE" "II6LacNAcβ,III4Fucα,IV3NeuAcα-LcOse4Cer" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:031)" " Galβ1-4GlcNAcβ1" " |" " 6" " Galβ1-3GlcNAcβ1-3Galβ1-4Glcβ1-1Cer" " 3 4" " | |" " NeuAcα2 Fucα1" "031/" "１次元 1H-NMR (031)" "031/" "ヒト 直腸腺がん(031)" "031/" "GL0130" 8.00 "N-ACETYLNEURAMINYLα2-3GALACTOSYLβ1-3(FUCOSYLα1-4)N-ACETYLGLUCOSAMINYLβ1-3GALACTOSYLβ1-4(FUCOSYLα1-3)N-ACETYLGLUCOSAMINYLβ1-3GALACTOSYLβ1-4GLUCOSYLCERAMIDE" "III3Fucα,V4Fucα,VI3NeuAcαnLcOse6Cer" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:031)" " Galβ1-3GlcNAcβ1-3Galβ1-4GlcNAcβ1-3Galβ1-4Glcβ1-1Cer" " 3 4 3" " | | |" "NeuAcα2 Fucα1 Fucα1" "031/" "１次元 1H-NMR (031)" "031/" "ヒト 直腸 腺がん(031)" "031/" "GL0131" 8.00 "N-ACETYLNEURAMINYLα2-3GALACTOSYLβ1-3(FUCOSYLα1-4)N-ACETYLGLUCOSAMINYLβ1-3(GALACTOSYLβ1-4N-ACETYLGLUCOSAMINYLβ1-6)GALACTOSYLβ1-4GLUCOSYLCERAMIDE" "II6Galβ1-4(Fucα1-3)GlcNAcβ,III4Fucα,IV3NeuAcα-LcOse4Cer" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " Fucα1 (REF:031)" " |" " 3" " Galβ1-4GlcNAcβ1" " |" " 6" " Galβ1-3GlcNAcβ1-3Galβ1-4Glcβ1-1Cer" " 3 4" " | |" " NeuAcα2 Fucα1" "031/" "１次元 1H-NMR (031)" "031/" "ヒト 直腸 腺がん(031)" "031/" "GL0132" 8.00 "N-ACETYLNEURAMINYLα2-3GALACTOSYLβ1-3(N-ACETYLNEURAMINYLα2-6)N-ACETYLGALACTOSAMINYLβ1-3GALACTOSYLα1-4GALACTOSYLβ1-4GLUCOSYLCERAMIDE" "V3NeuAcα,IV6NeuAcα-GbOse5Cer" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:032)" " NeuAcα2" " |" " 6" " Galβ1-3GalNAcβ1-3Galα1-4Galβ1-4Glcβ1-1Cer" " 3" " |" " NeuAcα2" "032/" "１次元 1H-NMR 500MHz (032)" "NEGATIVE FAB-MS (032)" "032/" "ヒト 赤血球, ニワトリ骨格筋(032)" "032/" "TLCパターン C/M/W(50:40:10)でGD1aとGDIbの間 脂肪酸-長鎖塩基組成 ﾋﾄ赤血球由来 C24:0-d18:1およびC22:0-d18:1 ﾆﾜﾄﾘ骨格筋由来 C18:0-d18:1 (032)" "032/" "GL0133" 8.00 "N-GLYCOLYLNEURAMINYLα2-3GALACTOSYLβ1-4N-ACETYLGLUCOSAMINYLβ1-3(GALACTOSYLβ1-4N-ACETYLGLUCOSAMINYLβ1-6)GALACTOSYLβ1-4N-ACETYLGLUCOSAMINYLβ1-3GALACTOSYLβ1-4GLUCOSYLCERAMIDE" "IV6LacNAcβ,VI3NeuGcα-nLcOse6Cer" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:034)" " Galβ1-4GlcNAcβ1" " |" " 6" " Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ1-3Galβ1-4Glcβ1-1Cer" " 3" " |" " NeuGcα2" "034/" "１次元 1H-NMR (034)" "FAB-MS (034)" "034/" "ウシ 赤血球(034)" "034/" "TLCパターン C/M/W(55:45:10)でGD1bの少し下 C/M/1.5N ｱﾝﾓﾆｱ(55:45:10)でGQ1bより下 ﾃﾄﾗﾋﾄﾞﾛﾌﾗﾝ/0.1%KCl(75:15)でGT1bとGQ1bの間脂肪酸組成 C18:1(22.3%),C22:1(13.5%),C18:0(11.1%),C16:0(10.8%) 長鎖塩基組成 C18:0(5%),C18:1(95%) (034)""" "034/" "GL0134" 8.00 "N-ACETYLNEURAMINYLα2-6GALACTOSYLβ1-4N-ACETYLGLUCOSAMINYLβ1-3(GALACTOSYLβ1-4N-ACETYLGLUCOSAMINYLβ1-6)GALACTOSYLβ1-4N-ACETYLGLUCOSAMINYLβ1-3GALACTOSYLβ1-4GLUCOSYLCERAMIDE" "IV6LacNAcβ,VI6NeuAcα-nLcOse6Cer" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:035)" " NeuAcα2 Galβ1-4GlcNAcβ1" " | |" " 6 6" " Galβ1-4GlcNAcβ1-3Galβ1-4lcNAcβ1-3Galβ1-4Glcβ1-1Cer" "035/" "500MHz １次元 PROTON (035)" "NEGATIVE FAB-MS (035)" "035/" "ヒト 胎便 (035)" "035/" "TLCパターン C/M/0.2%CaCl2(60:40:9)で血液型Ｉ型ｶﾞﾝｸﾞﾘｵｼﾄﾞのやや上 脂肪酸-スフィンゴシン組成 Ch16:0-d18:1,Ch22:0-d18:1,Ch24:0-d18:1 (035)""" "035/" "GL0135" 8.00 "N-ACETYLNEURAMINYLα2-3GALACTOSYLβ1-3(N-ACETYLNEURAMINYLα2-6)N-ACETYLGALACTOSAMINYLβ1-4(N-ACETYLNEURAMINYLα2-8N-ACETYLNEURAMINYLα2-3)GALACTOSYLβ1-4GLUCOSYLCERAMIDE" "II3(NeuAc)2α,III6NeuAcα,IV3NeuAcα-GgOse4Cer" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " NeuAcα2 (REF:036)" " |" " 6" " Galβ1-3GalNAcβ1-4Galβ1-4Glcβ1-1Cer" " 3 3" " | |" " NeuAcα2 NeuAcα2" " 8" " |" " NeuAcα2" "036/" "600MHz １次元 PROTON (036)" "NEGATIVE FAB-MS (036)" "036/" "ウシ脳 (036)" "036/" "抗コリン作動性ニューロン抗体と反応する (036)" "036/" "TLCパターン C/M/12mM MgCl2(5:4:1),C/M/12mM MgCl2/15M NH4OH(5:4:0.7:0.3)で GQ1bの下．脂肪酸組成 C16:0(1.2%),C18:0(91.3%),C20:0(4.4%),C22:0(3%)(036)" "036/" "GL0136" 8.00 "N-GLYCOLYLNEURAMINYLα2-3GALACTOSYLβ1-4N-ACETYLGLUCOSAMINYLβ1-3GALACTOSYLβ1-3N-ACETYLGALACTOSAMINYLβ1-4(N-GLYCOLYLNEURAMINYLα2-3)GALACTOSYLβ1-4GLUCOSYLCERAMIDE" "II3NeuAcα,VI3NeuAcα-nLMcOse6Cer" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:037)" " Galβ1-4GlcNAcβ1-3Galβ1-3Galβ1-4Galβ1-4Glcβ1-1Cer" " 3 3" " | |" " NeuAcα2 NeuAcα2" "037/" "１次元 1H NMR ２次元 HOHAHA (037)" "NEGATIVE FAB-MS (037)" "037/" "ラット脾臓 リンパ球 (037)" "037/" "TLCパターン C/M/0.2%CaCl2(60:40:9)でGD1bとGT1bの間、C/M/2.5N NH4OH(60:40:9)でGT1bより下．脂肪酸組成C18:0(4%),C20:0(9%),C21:0(2%),C22:0(14%),C23:0(5%),C24:1(44%), C24:0(22%) 長鎖塩基組成 d18:1が存在． (037)""" "037/" "GL0137" 8.00 "N-ACETYLNEURAMINYLα2-?GALACTOSYLβ1-?GALACTOSYLβ1-?GALACTOSYLα1-?GALACTOSYLβ1-?GLUCOSYLCERAMIDE" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:038)" " Galβ1-?Galβ1-?Galα1-?Galβ1-?Glcβ1-1Cer" " ?" " | （結合位置未同定）" " NeuAcα2" "038/" "１次元 500MHz 1H NMR (038)" "038/" "マウス 造血系細胞株 BM216 (038)" "038/" "TLCパターン C/M/0.2%CaCl2(6:4:1)でGD1aの少し上 (038)" "038/" "GL0138" 8.00 "N-ACETYLGALACTOSAMINYLβ1-4(N-ACETYLNEURAMINYLα2-3)GALACTOSYLβ1-3N-ACETYLGLUCOSAMINYLβ1-3(N-ACETYLGALACTOSAMINYLβ1-4)GALACTOSYLβ1-4GLUCOSYLCERAMIDE" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:039)" " GalNAcβ1-4Galβ1-3GlcNAcβ1-3Galβ1-4Glcβ1-1Cer" " 3 4" " | |" " NeuAcα2 GalNAcβ1" "039/" "１次元 400MHz 1H-NMR (039)" "NEGATIVE FAB-MS (039)" "039/" "ウシ脳 (039)" "039/" "筋萎縮性側索硬化症様の患者の血清 IgM と反応する (039)" "039/" "TLCパターン C/M/12mM MgCl2(5:4:1)でGD1aの少し上、C/M/12mM MgCl2/2.5M ammonia(50:40:7:3)でGD1bの少し上．脂肪酸-長鎖塩基組成 C18:0-d18:1またはC18:0-d20:1に相当するﾌﾗｸﾞﾒﾝﾄが検出．" "039/" "GL0139" 8.00 "N-ACETYLGALACTOSAMINYLβ1-4(N-ACETYLNEURAMINYLα2-3)GALACTOSYLβ1-3N-ACETYLGLUCOSAMINYLβ1-3(GALACTOSYLβ1-3N-ACETYLGALACTOSAMINYLβ1-4)GALACTOSYLβ1-4GLUCOSYLCERAMIDE" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:039)" " GalNAcβ1-4Galβ1-3GlcNAcβ1-3Galβ1-4Glcβ1-1Cer" " 3 4" " | |" " NeuAcα2 Galβ1-3GalNAcβ1" "039/" "１次元 400MHz 1H-NMR (039)" "NEGATIVE FAB-MS (039)" "039/" "ウシ脳 (039)" "039/" "筋萎縮性側索硬化症様の患者の血清 IgM と反応する (039)" "039/" "TLCパターン C/M/12mM MgCl2(5:4:1)でGD1aとGD1bの間 C/M/12mM MgCl2/2.5M ammonia(50:40:7:3)でGQ1bの上．脂肪酸-長鎖塩基組成 C18:0-d18:1またはC18:0-d20:1に相当するﾌﾗｸﾞﾒﾝﾄが検出． (039)" "039/" "GL0140" 8.00 "GALACTOSYLβ1-6GALACTOSYLβ1-6GLUCOSYLCERAMIDE" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:040)" " Galβ1-6Galβ1-6Glcβ1-1Cer" "040/" "１次元 500MHz 1H-NMR (040)" "NEGATIVE FAB-MS (040)" "040/" "ウニ卵 (Hemicentrotus pulcherrimus) (040)" "040/" "TLCパターン C/M/W(65:25:4)でCTHの下．脂肪酸組成 C22:1(61.4%),C22h:1(27.3%) 長鎖塩基組成 n-t18:0(92.9%)(040)" "040/" "GL0141" 8.00 "FUCOSYLα1-3N-ACETYLGALACTOSAMINYLβ1-4(FUCOSYLα1-3)N-ACETYLGLUCOSAMINYLβ1-4GLUCOSYLCERAMIDE" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:041)" " GalNAcβ1-4GlcNAcβ1-4Glcβ1-1Cer" " 3 3" " | |" " Fucα1 Fucα1" "041/" "2D-HOHAHA, DQF-COSY, １次元 1H 600MHz, NOESY(055)" "NEGATIVE FAB-MS (041)" "055/041/" "ウニ卵 (Hemicentrotus pulcherrimus) (041)" "041/" "TLCパターン 脂肪酸組成 C22:1(47.1%),C22h:1(25.1%),C23:1(10.3%) 長鎖塩基組成 n-t18:0(89.7%)(041)" "041/" "GL0142" 8.00 "GALACTOSYLβ1-6(FUCOSYLα1-3)GALACTOSYLβ1-6GALACTOSYLCERAMIDE" "II3Fucα-iGaOse3Cer" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:042)" " Galβ1-6Galβ1-6Galβ1-1Cer" " 3" " |" " Fucα1" "042/" "LSI-MS (042)" "042/" "Echinococcus multilocularis の METACESTODE (042)" "042/" "TLCパターン 脂肪酸組成 C16を主に含むものと、C18hを主に含むものがある．長鎖塩基組成 d18:0が主．(042)" "042/" "GL0143" 8.00 "FUCOSYLα1-3GALACTOSYLβ1-6GALACTOSYLCERAMIDE" "II3Fucα-iGaOse2Cer" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:042)" " Galβ1-6Galβ1-1Cer" " 3" " |" " Fueα1" "042/" "LSI-MS (042)" "042/" "Echinococcus multilocularis の METACESTODE (042)" "042/" "TLCパターン 脂肪酸組成 C16を主に含むものと、C18hを主に含むものがある．長鎖塩基組成 d18:0が主．(042)" "042/" "GL0144" 8.00 "GALACTOSYLβ1-3(FUCOSYLα1-4)N-ACETYLGLUCOSAMINYLβ1-3GALACTOSYLβ1-3(FUCOSYLα1-4)N-ACETYLGLUCOSAMINYLβ1-3GALACTOSYLβ1-4GLUCOSYLCERAMIDE" "III4Fucα,V4Fucα-LcOse6Cer" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:043)" " Galβ1-3GlcNAcβ1-3Galβ1-3GlcNAcβ1-3Galβ1-4Glcβ1-1Cer" " 4 4" " | |" " Fucα1 Fucα1" "043/" "１次元 1H-NMR 500MHz (043)" "POSITIVE FAB-MS (043)" "043/" "ヒト大腸 ADENOCARCINOMA CELL LINE COLO 205 (043)" "043/" "ヒト消化管 腺ガンに対する抗体 (NCC-ST-421)と反応 (043)" "043/" "TLCパターン 脂肪酸組成, 長鎖塩基組成 C24h:0-d18:1,C24h:1-d18:1,C24h:1-t18:0に相当する FAB-MSﾌﾗｸﾞﾒﾝﾄが主．(043)" "043/" "GL0145" 8.00 "2-KETO-3-DEOXY-D-GLYCERO-D-GALACTONONYLα2-3GALACTOSYLβ1-4GLUCOSYLCERAMIDE" "II3KDOα-LacCer" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:044)" " Galβ1-4Glcβ1-1Cer" " 3" " |" " KDNα2" "044/" "400MHz 1H-NMR １次元 HOHAHA (044)" "NEGATIVE FAB-MS (044)" "044/" "ニジマス精子 (044)" "044/" "TLCパターン C/M/0.2% CaCl2(55:45:10)で(NauAc)GM3より少し下．脂肪酸組成 16:0(95%),C24:1(5%) 長鎖塩基組成 ｄ18:1(044)" "044/" "GL0146" 8.00 "GALACTOSYLβ1-3GALACTOSYLα1-4GALACTOSYLβ1-4GLUCOSYLCERAMIDE" "III3Galβ-GbOse3Cer" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:045)" " Galβ1-3Galα1-4Galβ1-4Glcβ1-1Cer" "045/" "１次元 1H-NMR (500MHz) (045)" "NEGATIVE FAB-MS (045)" "045/" "Leishmania(L.) amazonensis の AMASTIGOTE (045)" "045/" "マクロファージへの寄生虫体 (AMASTIGOTE 及び PROMASTIGOTE)の侵入を本糖脂質と反応する抗体の１つが阻害する。(045)" "045/" "脂肪酸-長鎖塩基 C16:0-d18:1がFAB-MSから検出．(045)" "GL0147" 8.00 "GALACTOSYLβ1-4(FUCOSYLα1-3)N-ACETYLGLUCOSAMINYLβ1-3GALACTOSYLβ1-3(N-ACETYLNEURAMINYLα2-3)N-ACETYLGALACTOSAMINYLβ1-4GALACTOSYLβ1-4GLUCOSYLCERAMIDE" "II3NeuAcα,IV3Fucα1-3LacNAβ-GgOse4Cer" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:046)" " Galβ1-4GlcNAcβ1-3Galβ1-3GalNAcβ1-4Galβ1-4Glcβ1-1Cer" " 3 3" " | |" " Fucα1 NeuAcα2" "046/" "１次元 1H-NMR (400MHz) (046)" "NEGATIVE FAB-MS (046)" "046/" "ヒヨコの小腸組織 (046)" "046/" "神経系及び小腸組織の共通抗原と反応する抗体 (カエル皮膚を抗原として作製され たもの) 188C1 の抗原 (046)" "046/" "TLC パターン C/M/14mM MgCl2(5:4:1)でGD1aとGD1bの間 脂肪酸組成 16h:0(24.9%),C22h:0(31.3%) 長鎖塩基組成 t18:0(57.4%),d18:1(19.1%) (046)""" "046/" "GL0148" 8.00 "N-ACETYLGALACTOSAMINYLα1-3(FUCOSYLα1-2)GALACTOSYLβ1-3N-ACETYLGLUCOSAMINYLβ1-3GALACTOSYLβ1-3N-ACETYLGLUCOSAMINYLβ1-3GALACTOSYLβ1-4GLUCOSYLCERAMIDE" "VI2Fucα,VI3GalNAcα-LcOse6Cer" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:047)" " GalNAcα1-3Galβ1-3GlcNAcβ1-3Galβ1-3GlcNAcβ1-3Galβ1-4Glcβ1-1Cer" " 2" " |" " Fucα1" "047/" "１次元 1H-NMR (047)" "EI-MS メチル化糖脂質のEI-MS (047)" "047/" "純系ラット (DA, LOU/M) 小腸上皮細胞 (047)" "047/" "血液型Ａ活性 (047)" "047/" "TLC パターン, 分子モデルあり (047) 脂肪酸-長鎖塩基組成は、C16h:0-t18:0がFAB-MSで主．(047)" "047/" "GL0149" 8.00 "N-ACETYLNEURAMINYLα2-3GALACTOSYLβ1-3N-ACETYLGALACTOSAMINYLβ1-4(N-ACETYLNEURAMINYLα2-8N-GLYCOLYLNEURAMINYLα2-3)GALACTOSYLβ1-4GLUCOSYLCERAMIDE" "II3NeuAcα2-8NeuGcα,IV3NeuAcα-GgOse4Cer" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:048)" " Galβ1-3GalNAcβ1-4Galβ1-4Glcβ1-1Cer" " 3 3" " | |" " NeuAcα2 NeuGcα2" " 8" " |" " NeuAcα2" "048/" "１次元 1H-NMR (048)" "NEGATIVE FAB-MS (048)" "048/" "ウシ脳 (048)" "048/" "TLC パターン C/M/12mM MgCl2(5:4:1)でGT1bの少し上、C/M/12mM MgCl2/2.5M amm onia(50:40:7:3)でGT1bとGQ1bの間 (048) 脂肪酸-長鎖塩基 C18:0-d20:0が主．(048)" "048/" "GL0150" 8.00 "{6-O-[2'-(TRIMETHYLAMMONIO)-ETHYLPHOSPHORYL]}GALACTOSYLCERAMIDE" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:049)" " O-" " |" " (CH3)3N-CH2-CH2-O-P=O" " |" " O" " |" " 6" " Galβ1-1Cer" "049/" "1H-NMR 400MHz (049)" "FAB-MS (049)" "049/" "Neanthes diversicolor (海産 環形動物) (049)" "049/" "TLC パターン (049)" "049/" "GL0151" 8.00 "3-O-SULFO-N-ACETYLGALACTOSAMINYLβ1-3GALACTOSYLα1-3GALACTOSYLβ1-4GLUCOSYLCERAMIDE" "IV3HSO3-iGbOse4Cer" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:050)" " GalNAcβ1-3Galα1-3Galβ1-4GlcB1-1Cer" " 3" " |" " HSO3" "050/" "FT-IR 1240cm-1, 810cm-1 (050)" "DQF-COSY (050)" "NEGATIVE LSI (050)" "050/" "サル腎臓 (050)" "050/" "TLC パターン (050) 脂肪酸-長鎖塩基は、C24:0-t18:0が主(050)" "050/" "GL0152" 8.00 "3,4-O-CYCLICFATTY ACETAL-GALACTOSYLCERAMIDE" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:051)" " ／3" " R-HC Galβ1-1Cer R=CH3(CH2)14" " ＼4 CH3(CH2)16" " CH3C16H30" "051/" "FAB-MS (051)" "051/" "ヒト脳 (051)" "051/" "TLC パターン 脂肪酸組成 C16:0,C18:1,C18:0,C24:1(051) 長鎖塩基組成 d18:1(051)" "051/" "GL0153" 8.00 "4,6-O-CYCLICFATTY ACETAL-GALACTOSYLCERAMIDE" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:051)" " ／6" " CH3-(CH2)n-HC Galβ1-1Cer" " ＼4" " n=" "051/" "FAB-MS (051)" "051/" "ヒト脳 (051)" "051/" "TLC パターン 脂肪酸組成 C16:0,C18:1,C18:0,C24:1(051) 長鎖塩基組成 d18:1(051)" "051/" "GL0154" 8.00 "GALACTOSYLα1-2GALACTOSYLβ1-4(2-AMINOETHYLPHOSPHONYL-6)GLUCOSYLCERAMIDE" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:052)" " 2AEPn" " |" " 6" " Galα1-2Galβ1-4Glcβ1-1Cer" "052/" "FAB-MS (052)" "052/" "Aplysia juliana (アメフラシの一種)(052)" "052/" "脂肪酸組成 C16:0(61.9%),C18:0(24.2%)(052) 長鎖塩基組成 d18:1(19.4%),分枝d19:1(54.4%)(052)" "052/" "GL0155" 8.00 "[3,4-O-(S-1-CARBOXYETHYLIDENE)]GALACTOSYLβ1-3N-ACETYLGALACTOSAMINYLα1-3[6'-O-(2-AMINOETHYLPHOSPHONYL)GALACTOSYLα1-2](2-AMINOETHYLPHOSPHORYL1-6)GALACTOSYLβ1-3GLUCOSYLCERAMIDE" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:053)" " 2AEPr" " H3C O |" " ＼ ／ ＼4 6" " C Galβ1-3GalNAcα1-3Galβ1-4Glcβ1-1Cer" " ／ ＼ ／3 2" " HOOC O |" " 2-AEPn-6Galα1" "053/" "１次元 1H-NMR (400MHz) (053)" "FAB-MS (053)" "053/" "Aplysia kurodai(アメフラシの一種) (053)" "053/" "脂肪酸組成 C16:0(92%),C18:0(8%)(053) 長鎖塩基組成 d18:1(37%),anteiso d19:1(55%)(053)" "053/" "GL0156" 8.00 "[3,4-O-(S-1-CARBOXYETHYLIDENE)]GALACTOSYLβ1-3N-ACETYLGALACTOSAMINYLα1-3(FUCOSYLα1-2)(2-AMINOETHYLPHOSPHONYL1-6)GALACTOSYLβ1-4GLUCOSYLCERAMIDE" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:053)" " 2AEPn" " H3C O |" " ﾒ ／ ＼4 6" " C Galβ1-3GalNAcα1-3Galβ1-4Glcβ1-1Cer" " ﾄ ＼ ／3 2" " HOOC O |" " Fucα1" "053/" "１次元 1H-NMR (400MHz) (053)" "FAB-MS (053)" "053/" "Aplysia kurodai(アメフラシの一種) (053)" "053/" "脂肪酸組成 C16:0(94%),C17:0(3%),C18:0(3%)(053) 長鎖塩基組成 d18:1(39%),anteiso d19:1(48%)(053)" "053/" "GL0157" 8.00 "CHOLINEPHOSPHORYL-6GALACTOSYLCERAMIDE" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:054)" " N-tMAEPr" " |" " 6" " Galβ1-1Cer" " (N-tMAEPr:N-trimethylaminoethylphosphoryl)" "054/" "960 cm-1 (054)" "FAB-MS (054)" "054/" "ミミズ Pheretima hilgendorfi (054)" "054/" "TLCパターン 脂肪酸組成 C22:0(49.3%),C24:0(25.0%)(054) 長鎖塩基組成 分枝d18:1(54.7%),d18:1(24.5%),分枝d19:1(20.8%)(054)" "054/" "GL0158" 8.00 "CHOLINEPHOSPHORYL-6GALACTOSYLβ1-6GLUCOSYLCERAMIDE" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:054)" " N-tMAEPr" " |" " 6" " Galβ1-6Glcβ1-1Cer" " (N-tMAEPr:N-Trimethylaminoethylphosphoryl)" "054/" "FAB-MS (054)" "054/" "ミミズ Pheretima hilgendorfi (054)" "054/" "TLCパターン 脂肪酸組成 C22:0(56.0%),C24:0(20.9%)(054) 長鎖塩基組成 分枝ｄ18:1(52.5%),d18:1(18.7%),分枝19:1(28.8%)(054)" "054/" "GL0159" 8.00 "GALACTOSYLβ1-3N-ACETYLGALACTOSAMINYLβ1-4(DE-N-ACETYLNEURAMINOYLα2-3)GALACTOSYLβ1-4GLUCOSYLβ1-1CERAMIDE" "DE-N-ACETYLATED GM1,II3NeuNα-GgOse4Cer" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:056)" " Galβ1-3GalNAcβ1-4Galβ1-4Glcβ1-1Cer" " 3" " |" " NeuNH2α2" "056/" "１次元 1H-NMR (056)" "FAB-MS (056)" "056/" "ウシ脳 (056)" "056/" "TLCパターン, コレラトキシンとの反応性 (056)" "056/" "GL0160" 8.00 "MANNOSYLβ1-4(FUCOSYLα1-3)GLUCOSYLCERAMIDE" "I3αFuc,M1Ose2Cer" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:057)" " Manβ1-4Glcβ1-Cer" " 3" " |" " Fucα1" "057/" "400MHz 1H-NMR : β-GLUCOSE : 4.21ppm(J1,2=7.9Hz), β-MANNOSE : 4.65ppm, α-FUCOSE : 5.26ppm(J1,2=3.6Hz), FUCOSE H-5 : 4.30ppm (057)" "(-)FAB-MS : [M-H]-=1104,1090,1076, [M-Fuc-H)-=958,944,930, [M-Man-H]-=942, 928,914, [M-Fuc-Man-H]-=796,782,768, CERAMIDE=634,620,606 (057)" "057/" "Laminata armigera(陸生節足動物の一種)(全組織を抽出)(057)" "057/" "脂肪酸組成 : 直鎖酸 27.9%(16:0,22:0,23:0,24:0), 2-ハイドロキシ酸 32.6%(22:0,23:0,24:0), 3-ハイドロキシ酸 39.5%(22:0,23:0,24:0),長鎖塩基組成: 分枝 d17:1 8.6%, d17:1 28.4%, d17:0 15.3% ,分枝 d18:1 23.5%,d18:1 24.2%""" "GL0161" 8.00 "CHOLINEPHOSPHORYL-6(MANNOSYLα1-4)GALACTOSYL1-6GALACTOSYLβ1-1CERAMIDE" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " O (REF:058)" " + ｾ" " (CH3)3N-CH2-CH2O-P-O-6Galβ1-6Galβ1-1Cer" " | 4" " OH |" " Manα1" "058/" "OH- ABSORPTION: 3400cm-1, AMIDE I: 1620cm-1, AMIDE II: 1540cm-1, PHOSPHATE BOND: 1220cm=1, CHOLINE: 960cm-1 (058)" "500MHz 1H-NMR : ホスフォコリンのCH2 : 3.56ppm,4.12ppm, β-Galのアノメリックプロトン : 4.10ppm(J1,2=8.7Hz), 4.24ppm(J1,2=7.5Hz), α-Manのアノメリックプロトン : 4.77ppm (058)" "(+)FAB-MS : M = 1273,1287,1301, ヘキソースに結合するコリンの存在を示す M/Z = 490,506,652,668,1111,1125,1139, 糖類の中間にあるヘキサースに結合するコリンの存在を示す M/Z = 1111,1125,1139 (058)" "058/" "ミミズ Pheretima hilgendorfi (全組織を抽出)(058)" "058/" "主な脂肪酸 : 24:0 21.8%, 23:0 11.2%, 22:0 51.7%, 長鎖塩基 :分枝 d18:1 53.4%, d18:1 20.0%, 分枝 d19:1 26.4%" "GL0162" 8.00 "CHOLINEPHOSPHORYL-6GALACTOSYLβ1-6GALACTOSYLβ1-6GALACTOSYLβ1-1CERAMIDE" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " O (REF:058)" " + ｾ" " (CH3)3N-CH2-CH2O-P-O-6Galβ1-6Galβ1-6Galβ1-1Cer" " |" " OH" "058/" "OH ABSORPTION:3400cm-1, AMIDE I:1620cm-1, AMIDE II:1540cm-1, PHOSPHATE BOND:1220cm=1, CHOLINE:960cm-1 (058)" "500MHz 1H-NMR: ホスフォコリンのCH2: 3.65ppm,4.18ppm, β-Galのアノメリックプロトン: 4.05ppm(J1,2=6.1Hz),4.17ppm(J1,2=7.1Hz),4.19ppm(J1,2=6.6Hz) (058)" "(+)FAB-MS: M = 1273,1287,1301, ヘキソースに結合するコリンの存在を示す M/Z = 328,344,490,506,652,668 (058)" "058/" "ミミズ (Pheretima hilgendorfi) 全組織から" "脂肪酸 主なもの : 22:0 50.8%, 23:0 11.9%, 24:0 21.7%, 長鎖塩基 : 分枝 d18:1 55.4%, d18:1 19.3%, 分枝 d18:1 25.3%" "GL0163" 8.00 "N-ACETYLGALACTOSAMINYLβ1-4(N-ACETYLNEURAMINYLα2-3)GALACTOSYLβ1-3-N-ACETYLGALACTOSAMINYLβ1-4(N-GLYCOLYLNEURAMINYLα2-3)GARACTOSYLβ1-4GLUCOSYLβ1-1CERAMIDE" "GalNAc-GD1a(Neu5Ac/Neu5Gc)" "IV4GalNAcIV3Neu5AcII3Neu5GcGgOse4Cer" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:059)" " GalNAcβ1-4Galβ1-3GalNAcβ1-4Galβ1-4Glcβ1-1Cer" " 3 3" " | |" " NeuAcα2 NeuGcα2" "059/" "データ No.94059-0048の GalNAc-GD1a(NeuGc/NeuAc)との混合物で測定｡ 500MHz 1H-NMR 及び 125Hz 13C-NMR, HSQC, ROESY (059)" "059/" "ウシ脳 (ウシ脳全ガングリオシドの約 0.12%の含量)(059)" "059/" "GL0164" 8.00 "N-ACETYLGALACTOSAMINYLβ1-4(N-GLYCOLYLNEURAMINYLα2-3)GALACTOSYLβ1-3-N-ACETYLGALACTOSAMINYLβ1-4(N-ACETYLNEURAMINYLα2-3)GALACTOSYLβ1-4GLUCOSYLCERAMIDE" "GalNAc-GD1a(Neu5Gc/Neu5Ac)" "IV4GalNAcIV3Neu5GcII3Neu5AcGgOse4Cer" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:059)" " GalNAcβ1-4Galβ1-3GalNAcβ1-4Galβ1-4Glcβ1-1Cer" " 3 3" " | |" " NeuGcα2 NeuAcα2" "059/" "データ No.94059-0047の GalNAc-GD1a(NeuAc/NeuGc)との混合物で測定｡ 500MHz 1H-NMR,125Hz 13C-NMR, HSQC, ROESY (059)" "059/" "ウシ脳 (ウシ脳全ガングリオシドの約 0.08%の含量)(059)" "059/" "GL0165" 8.00 "GALACTOSYLα1-3(FUCOSYLα1-2)GALACTOSYLβ1-3GALACTOSYLβ1-4GLUCOSYLβ1-1CERAMIDE" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:060)" " Galα1-3Galβ1-3Galβ1-4Glcβ1-1Cer" " 2" " |" " Fucα1" "060/" "400MHz 1H-NMR : アノメリックプロトン Glc(β1-1): 4.2ppm J1,2=7.7Hz, Gal(β1-4): 4.3ppm J1,2=7.7Hz, Gal(β1-3): 4.6ppm J1,2=7.7Hz, Gal(α): 5.0ppm J1,2=4.0Hz, Fuc: 5.1ppm J1,2=3.7Hz(060)" "(-)FAB-MS [M-H]-: 1456,1430(C22h:o), 1474,1448(C24h:o) (060)" "060/" "アフリカツメガエル Xenopus laevis 卵(060)" "060/" "Ｂ型血液型活性あり｡ Xenopus laevis の blastula cell が抗Ｂ抗体で染色される｡ (060)" "060/" "セラミドの組成により TLC上２つのバンドに分れる｡ XN-1 ハイドロキシ脂肪酸 46.3% (C22h:0, C24h:0が主), XN-2 ハイドロキシ 66.3%(C22h:0, C24h:0, C24h:1)""" "GL0166" 8.00 "N-ACETYLGALACTOSAMINYLβ1-3GALACTOSYLα1-3(FUCOSYLα1-2)GALACTOSYLβ1-3-N-ACETYLGALACTOSAMINYLβ1-4GALACTOSYLβ1-4GLUCOSYLCERAMIDE" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:061)" " GalNAcβ1-3Galα1-3Galβ1-3GalNAcβ1-4Galβ1-4Glcβ1-1Cer" " 2" " |" " Fucα" "061/" "400MHz 1H-NMR: 2つのαｱﾉﾒﾘｯｸﾌﾟﾄﾝ: 5.07ppm(3J=2.8Hz),5.00ppm(3J<1Hz), Fucの H-5の QUARTET: 4.15ppm (3J=13.4Hzと6.3Hz), FucのメチルDOUBLET: 1.05ppm (3J=6.4Hz), βｱﾉﾒﾘｯｸﾌﾟﾛﾄﾝ: 4.51ppm(3J=9.6Hz),4.48ppm(3J=9.2Hz)(061)" "完全メチル化物と完全メチル化／還元体のEI (061)" "061/" "ラット (Wister/Furth) 精巣(061)" "061/" "血液型Ｂ活性 (061)" "061/" "セラミド組成:スフィンゴシンとフィトスフィンゴシン,16:0-24:0のハイドロキシ酸及び直鎖酸""" "GL0167" 8.00 "HSO3-GALACTOSYLβ1-3N-ACETYLGALACTOSAMINYLβ1-3GALACTOSYLα1-3GALACTOSYLβ1-4GLUCOSYLCERAMIDE" "iGb5CerV3-sulfate" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:062)" " Galβ1-3GalNAcβ1-3Galα1-3Galβ1-4Glcβ1-1Cer" " 3" " |" " HSO3-" "062/" "硫酸エステル基(ヘキソースのエカトリアルエステル): 1240cm-1,810cm-1(062)" "400MHz 1H-NMR: DQCOSY, NOE (062)" "LSIMS (CID LINED SCAN も含む) [M-H]-=1597,1569,1541,1523,1467(ｾﾗﾐﾄﾞの違い)[OSO3H]-=97 (062)" "062/" "ラット (Sprague Dawley) 脾臓(062)" "062/" "(062)" "062/" "GL0168" 8.00 "6'-O-PHOSPHOCHOLINE-α-GLUCOPYRANSYL-(1'-3)-1,2-DIACYL-sn-GLYCEROL" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " O (REF:063)" " ｾ" " O H2C-O-C-(CH2)14-CH3" " ｾ |" " CH3-(CH2)14-C-O-CH" " |" " H2C-Glc" " 6" " | +" " PO3-CH2-CH2-N(CH3)2" "063/" "(063)" "400MHz 1H-NMR (063)" "LSIMS TANDEM MS (COLLISION-ACTIVATED DISSOCIATION MS) (063)" "063/" "Mycoplasma Fermentans" "GL0169" 8.00 "2-KETO-3-DEOXY-D-GLYCERO-D-GALACTO-NONONYLα2-3GALACTOSYLβ1-3N-ACETYLGALACTOSAMINYLβ1-4(2-KETO-3-DEOXY-D-GLYCERO-D-GALACTO-NONONYLα2-3)GALACTOSYLβ1-4GLUCOSYLCERAMIDE" "KDNGDla" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:064)" " Galβ1-3GalNAcβ1-4Galβ1-4Glc-Cer" " 3 3" " | |" " KDNα2 KDNα2" "064/" "500MHz 1H-NMR: 末端KDN: H-3ax 1.55ppm,H-3eq 2.45ppm, 内側KDN: H-3eq 2.61ppm (064)" "FAB-MS 糖脂質そのままと, メチル化物｡ (064)" "064/" "ニジマス精巣(064)" "064/" "モノクロナール抗体mAb.Kdn3Gと反応(KDNα2-3Galβ1-がエピトープ)この抗体と反応するKDNガングリオシドは,精子形成の過程で発現が変化する｡KDNGDla は精子形成の初期から発現する｡成熟精子には含まれない｡ (064)" "064/" "セラミド組成の違いで TLC上２バンドになる。A: C16:0 20% /C24:0 80% と d18:1 80% t18:0 20% b: C16:0 1% /C24:0 99% と d18:1 97% t18:0 3% (064)" "064/" "GL0170" 8.00 "2-KETO-3-DEOXY-D-GLYCERO-D-GALACTO-NONONYLα2-3GALACTOSYLβ1-3N-ACETYLGALACTOSAMINYLβ1-4(N-ACETYLNEURAMINYLα2-3)GALACTOSYLβ1-4GLUCOSYLCERAMIDE" "(KDN,Neu5Ac)GD1a,II3NeuAc,IV3KDN-GgOse4Cer" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:064)" " Galβ1-3GalNAcβ1-4Galβ1-4Glc-Cer" " 3 3" " | |" " KDNα2 Neu5Acα2" "064/" "500MHz 1H-NMR:末端KDN:H-3ax 1.55ppm,H-3eq 2.45ppm, 内側NeuAc:H-3eq 2.61ppm (064)" "FAB-MS 糖脂質そのまま及び, メチル化物｡ (064)" "064/" "モノクロナール抗体mAb.Kdn3Gと反応(KDNα2-3Galβ1-がエピトープ)この抗体と反応するKDNガングリオシドは,精子形成の過程で発現が変化する｡KDN/NeuAcGD1aは精子形成の初期から発現する｡成熟精子には含まれない｡(064)" "064/" "セラミド組成:C24:1 99% - d18:1 80% /t18:0 20%, C16:0 36% /C24:1 64% - d18:1 /t18:0 (064)" "064/" "GL0171" 8.00 "N-ACETYLNEURAMINYLα2-3GALACTOSYLβ1-3N-ACETYLGALACTOSAMINYLβ1-4(2-KETO-3-DEOXY-D-GLYCERO-D-GALACTO-NONONYLα2-3)GALACTOSYLβ1-4GLUCOSYLCERAMIDE" "(Neu5Ac,KDN)GD1a,II3KDN,IV3NeuAc-GgOse4Cer" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:064)" " Galβ1-3GalNAcβ1-4Galβ1-4Glc-Cer" " 3 3" " | |" " Neu5Acα2 KDNα2" "064/" "500MHz 1H-NMR:末端NeuAc:H-3eq 2.72ppm,内側KDN: H-3ax 1.62ppm,H-3eq 2.59ppm (064)" "FAB-MS 糖脂質そのままと, メチル化物｡ (064)" "064/" "ニジマス精巣(064)" "064/" "モノクロナール抗体mAb.Kdn3Gと反応(KDNα2-3Galβ1-がエピトープ)この抗体と反応するKANガングリオシドは,精子形成の過程で発現が変化する｡KDN/NeuAcGD1a は精子形成の初期から発現する｡成熟精子には含まれない｡(064)" "064/" "セラミド C24:1 99% - d18:1 80% /t18:0 20%, C16:0 36% /C24:1 64% - d18:1 /t18:0" "GL0172" 8.00 "2-KETO-3-DEOXY-D-GLYCERO-D-GALACTO-NONONYLα2-3GALACTOSYLβ1-3(2-KETO-3-DEOXY-D-GLYCERO-D-GALACTO-NONONYLα2-6)N-ACETYLGALACTOSAMINYLβ1-4GALACTOSYLβ1-4GLUCOSYLCERAMIDE" "KDN GD1α,III6KDN,IV3KDN-GgOse4Cer" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " KDNα2 (REF:064)" " |" " 6" " Galβ1-3GalNAcβ1-4Galβ1-4Glc-Cer" " 3" " |" " KDNα2" "064/" "500MHz 1H-NMR: 末端KDN: H-3ax 1.19ppm,H-3eq 2.53ppm, 内側KDN:H-3ax 1.30ppm,H-3eq 2.62ppm (064)" "FAB-MS 糖脂質そのままと, メチル化物｡ (064)" "064/" "ニジマス精巣(064)" "064/" "モノクロナール抗体mAb.kdn3Gと反応 KDNα2-3Galβ1-がエピトープ)この抗体と反応するKDNガングリオシドは精子形成過程で発現が変化する｡KDN GDlαは SPERMIATION の２カ月前になるまで発現しない｡成熟精子には含まれない｡ (064)" "064/" "セラミド組成 C16:0 1% / C24:1 99% - d18:1 97% / t18:0 3%, C16:0 54% / C24:1 46% - d18:1 /t18:0 の２種が TLC 上別離される｡(064)" "064/" "GL0173" 8.00 "2-KETO-3-DEOXY-D-GLYCERO-D-GALACTO-NONONYLα2-3GALACTOSYLβ1-3(N-ACETYLNEURAMINYLα2-6)-N-ACETYLGALACTOSAMINYLβ1-4GALACTOSYLβ1-4GLUCOSYLCERAMIDE" "(KDN,Neu5Ac)GD1α,III6NeuAc,IV3KDN-GgOse4Cer" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " Neu5Acα2 (REF:064)" " |" " 6" " Galβ1-3GalNAcβ1-4Galβ1-4Glc-Cer" " 3" " |" " KDNα2" "064/" "500MHz 1H-NMR:末端KDN:H-3ax 1.18ppm,H-3eq 2.51ppm, 内側NeuAc:H-3ax 1.33ppm, H-3eq 2.75ppm (064)" "FAB-MS. 糖脂質そのままと, メチル化物｡ (064)" "064/" "ニジマス精巣(064)" "064/" "モノクロナール抗体mAb.Kdn3Gと反応(KDNα2-3Galβ1-がエピトープ)この抗体と反応するKDNガングリオシドは精子形成過程で発現が変化する｡KDN/NeuAc GD1αはSPERMIATIONの２カ月前になるまで発現しない｡成熟精子には含まれない｡(064)" "064/" "セラミド組成 C16:0 2% / C24:1 98% - d18:1 97% / t18:0 3%,C16:0 71% / C24:1 29% - d18:1 /t18:1 (064)" "064/" "GL0174" 8.00 "3-O-METHYLGALACTOSYLα1-3[6'-O-(2-AMINOETHYLPHOSPHONYL)GALACTOSYLα1-2](2-AMINOETHYLPHOSPHONYL-6)GALACTOSYLβ1-4(2-AMINOETHYLPHOSPHONYL-6)GLUCOSYLCERAMIDE" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " 2-AEP 2-AEP (REF:065)" " | |" " 6 6" " Me-3Galα1-3Galβ1-4Glcβ1-1Cer" " 2" " |" " 2-AEP-6Galα1" "065/" "400MHz 1H-NMR (HF処理後)｡ 及びHF処理前後の試料を混合してCOSY分析｡ AEP結合の影響のデータあり｡ (065)" "(-)FAB-MS. 糖脂質そのままと, HF処理で AEPをはずしたもののスペトル (065)""" "065/" "アメフラシ Aplysia kurodai 卵 (065)" "065/" "セラミドの組成: 脂肪酸 16:0(43.9%),17:0(7.6%),18:0(45.0%), 長鎖塩基 : d18:1(21.7%),16-METHYL d19:1(45.5%) 長鎖塩基 d18:1 21.7% 16-METHYL d19:1 45.5%" "GL0175" 8.00 "MANNOSILα1-2GALACTOSYLα1-6GLUCOSAMINYLα1-4GLUCOSYLα1-1CERAMIDE" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:066)" " Manα1-2Galα1-6GlcNH2α1-4Glcα1-1Cer" "066/" "1H-NMR, 13C-NMR (066)""" "LD-MS (066)" "066/" "Sphingomonas paucimobilis (グラム陰性菌の一種で従来は Pseudomonas paucimobilis と呼ばれていたものと同一)(066)" "066/" "セラミド組成: 脂肪酸:ヒドロキンミリスチン酸 C14H:0, 長鎖塩基:スフィンガニンとERUTHRO-1,3-DIHYDROXY-2-AMINO-CIS-13,14-METHYLENEOCTADECANE" "GL0176" 8.00 "GALACTOFURANOSYLβ1-3(2-AMINOETHYLPHOSPHONYL-6)MANNOSILα1-3MANNOSYLα1-4(2-AMINOETHYLPHOSPHONYL-6)GLUCOSAMINYLα1-6INOSITOL1-PHOSPHOCERAMIDE" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:068)" " Galfβ1-3Manα1-3Manα1-4GlcNH2α1-6-myo-inositol-1-OPO3-Cer" " 6 6" " | + | +" " OPO2CH2CH2NH3 OPO2CH2CH2NH3" "068/" "Leptomonas samueli (068)" "068/" "GL0177" 8.00 "2-AMINOETHYLPHOSPHONYL-6MANNOSILα1-3MANNOSYLα1-4(2-AMINOETHYLPHOSPHONYL-6)GLUCOSAMINYLα1-6INOSITOL1-PHOSPHOCERAMIDE" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " + + (REF:068)" " OPO2CH2CH2NH3 OPO2CH2CH2NH3" " | (2-AEP) | (2-AEP)" " 6 6" " Manα1-3Manα1-4GlcNH2α1-6-myo-inositol-1-OPO3-Cer" "068/" "600MHz 1HNMR : COSY, ROESY, COSY-45, 13C-NMR(068)" "FAB-MS (068)" "068/" "Leptomonas samueli (原生動物,鞭毛虫類の一種) (068)" "068/" "セラミドの組成 : C18:0 / C24:0 - C20 PHYTOSPHINGOSINE (068)" "068/" "GL0178" 8.00 "FUCOSYLα1-4(3-PHOSPHOETHANOLAMINYL)-INOSITOLα1-PHOSPHOCERAMIDE" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:067/069)" " Fucα1-4Insα1-OPO3-Cer" " 3" " |" " PO3-O-CH2-CH2-NH2" "067/069/" "1H-NMR 31P-NMR HOHAHA, COSY, NOE, ROESY, 2-D long-range 1H{31P}scalarcoirelation (069)" "LAIMS, CID MS/MS (069) FAB-MS, FAB MS/MS (067)" "067/069/" "Tritrichomonas foetus (067/069)" "067/069/" "セラミド : C16:0 - d18:0 / d18:1 (067)" "067/" "GL0179" 8.00 "3-PHOSPHO-INOSITOL-PHOSPHOCERAMIDE" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:069)" " Ins1-OPO3-Cer" " 3" " |" " OPO3" "069/" "CID-MS (067), LAIMS (069)" "067/069/" "Tritrichomonas foetus (067/069) Trichomonas vaginalis (069)" "067/069/" "セラミド : C16:0 - d18:0 / d18:1" "GL0180" 8.00 "3-PHOSPHOETHANOLAMINYL-INOSITOLα1-PHOSPHOCERAMIDE" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:069)" " Insα1-OPO3-Cer" " 3" " |" " NH2-CH2-CH2-O-PO3" "069/" "(069)" "CID MS/MS (069)" "069/" "Trichomonas vaginalis (069)" "069/" "GL0181" 8.00 "GLUCRONYLα1-3GLUCOSYLα1-4XYLOSYLβ1-4XYLOSYLβ1-4(RHAMNOSYLα1-3)MANNOSYLα1-2MANNOSYLα1-3(2-AMINOETHYLPHOSPHONYL-6)MANNOSYLα1-3MANNOSYLα1-4(2-AMINOETHYLPHOSPHONYL-6)GLUCOSAMINYLα1-6INOSITOL(1or2)-PHOSPHOCERAMIDE" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:070)" " 2-AEP 2-AEP" " | |" " 6 6" "Glcα1-4Xylβ1-4Xylβ1-4Manα1-2Manα1-3Manα1-3Manα1-4GlcNα1" " 3 3 |" " | | 6" "αGlcA Rhaα1 Ins(1or2)-OPO3" " -Cer" "070/" "1H-NMR(500MHz) 13C-NMR : COSY, TOCSY, ROESY (070)" "FAB-MS (070)" "070/" "Leptomonas samueli (原生動物, 鞭毛虫類の一種) (070)" "070/" "GL0182" 8.00 "XYLOSYLβ1-3XYLOSYLβ1-4XYLOSYLβ1-4(RHAMNOSYLα1-3)MANNOSYLα1-2MANNOSYLα1-3(2-AMINOETHYLPHOSPHONYL-6)MANNOSYLα1-3MANNOSYLα1-4(2-AMINOETHYLPHOSPHONYL-6)GLUCOSAMINYLα1-6INOSITOL(1or2)-PHOSPHOCERAMIDE" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:070)" " 2-AEP 2-AEP" " | |" " 6 6" "Xylβ1-3Xylβ1-4Xylβ1-4Manα1-2Manα1-3Manα1-3Manα1-4GlcNα1" " 3 |" " | 6" " αRha1 Ins(1or2)-OPO3" " -Cer" "070/" "500MHz 1H-NMR, 13C-NMR : TOCSY, COSY, ROESY (070)" "FAB-MS (070)" "070/" "Leptomonas samueli (原生動物, 鞭毛虫類の一種) (070)" "070/" "GL0183" 8.00 "XYLOSYLβ1-4XYLOSYLβ1-4(RHAMNOSYLα1-3)MANNOSYLα1-2MANNOSYLα1-3(2-AMINOETHYLPHOSPHONYL-6)MANNOSYLα1-3MANNOSYLα1-4(2-AMINOETHYLPHOSPHONYL-6)GLUCOSAMINYLα1-6INOSITOL(1or2)-PHOSPHOCERAMIDE" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:070)" " 2-AEP 2-AEP" " | |" " 6 6" "Xylβ1-4Xylβ1-4Manα1-2Manα1-3Manα1-3Manα1-4GlcNα1" " 3 |" " | 6" " Rhaα1 Ins(1or2)-PO3-Cer" "070/" "500MHz 1H-NMR, 13C-NMR : TOCSY, COSY, ROESY (070)" "FAB-MS (070)" "070/" "Leptomonas samueli (原生動物, 鞭毛虫類の一種) (070)" "070/" "GL0184" 8.00 "GLYCOSYLCERAMIDE, (2S,3R,4E,8E,10E)-1-(β-DGLUCOPYRANOSYLOXY)-3-HYDROXY-2[((R)-2-HYDROXYDOCOSANOYL)AMINO]-9-METHYL-4,8,10-OCTADECATRIENE" "OPHIDIACEREBROSIDE" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " O OH (REF:071)" " ｾ |" " C−CH-CH2-(CH2)n-CH2-CH3 n=15,16,17,18,19" " | (上の化学名はN=17の場合)" " NH OH H H H (注:長鎖塩基が新奇)" " | | | | |" "Glcβ1-1CH2-C−C−C=C-CH2-CH2-C=C-C=C-CH2-CH2-(CH2)4-CH2-CH3" " | | | | |" " H H H CH3 H" "071/" "ヒトデ Ophidiaster ophidiamus (全組織から) (071)" "071/" "L1210 マウス白血病細胞に対して細胞毒性を示す｡(071)" "071/" "GL0185" 8.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " Manα1-2Manα1-2Manα1-6Manα1-4GlcNH2-myoIno (REF:072)" " | | | |" " PO4 +/- X EtN/2-AEP PO4" " | |" " EtN/2-AEP CH2 O" " | | ｾ (C16:O/C18:O)" " PROTEIN CH-O-C-(CH2)n-CH3" " |" " EtN:ETHANOLAMINEPHOSPHATE CH2-O-O-(CH2)n-CH3" "2AEP:2-AMINOETHYLPHOSPHONATE (C16:O)" "072/" "500MHz 1H-NMR (072)" "ELECTROSPRAY-MS (072)" "072/" "Trypanosoma cruziの Epimastigoteの虫体(上鞭毛期)(ジャガス病を起こす寄生虫) (072)" "072/" "寄生虫の表面にあるｼｱﾙ酸ﾚｾﾌﾟﾀｰと考えられているﾑﾁﾝの GPIｱﾝｶｰ部分｡寄生虫の生活環による形態変化により脂質部分に変化が見られる｡ 本物質は,上鞭毛期の虫体に多い｡(発育終末ﾄﾘﾊﾟﾉｿｰﾏ型ではｲﾉｼﾄｰﾙﾎｽﾎｾﾗﾐﾄﾞ型が70%を占める｡)(072)" "072/" "GL0186" 8.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " Manα1-2Manα1-2Manα1-6Manα1-4GlcNH2-myoIno (REF:072)" " | | | |" " PO4 +/- X EtN/2-AEP PO4" " | |" " EtN/2-AEP CH2" " | | (C16:O/C18:O)" " PROTEIN CH-O-C-(CH2)n-CH3" " |" " EtN:ETHANOLAMINEPHOSPHATE CH2-O-(CH2)n-CH3" " 2AEP:2-AMINOETHYLPHOSPHONATE (C16:O)" "072/" "500MHz 1H-NMR (072)" "ELECTROSPRAY-MS (072)" "072/" "Tripanosoma cruziのMetacyclic Trypomastigote虫体(発育終末トリパノソーマ型) (072)" "072/" "寄生虫の表面にあるシアル酸レセプターと考えられているムチンの GPIアンカー。 発育終末トリパノソーマ型では 30% が本構造,残りの 70% はイノシトールホスホセラミド型である(072)" "072/" "GL0187" 8.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " PROTEIN (REF:072)" " |" " EtN/2-AEP" " |" " PO4 EtN/2-AEP" " | |" " Manα1-2Manα1-2Manα1-6Manα1-4GlcNH2-myoIno-PO4-Cer" " |" " +/-X" "072/" "500MHz 1H-NMR (072)" "ELECTROSPRAY-MS (072)" "072/" "Tripanosoma cruziのMetacyclic Trypomastigote虫体(発育終末トリパノソーマ型) (072)" "072/" "寄生虫表面のシアル酸レセプターと考えられているムチンの GPIアンカー｡ 本構造(イノシトールホスホセラミド)は metacyclic typomastigote form での主要成分 (70%)である｡(072)" "072/" "セラミド" "GL0188" 8.00 "1-GLUCOPYRANOSYL-2-(2-HYDROXYTETRACOSANOYLAMINO)-1,3,4-HEXADECANTRIOL" "ACANTHACEREBROSIDE A" "C46H91O10N" 46.00 91.00 10.00 1.00 0.00 0.00 817.00 " (REF:001/004)" " Glc-O-CH2-CH-CH-CH-(CH2)11-CH3" " | | |" " NH OH OH" " |" " O=C-CH-(CH2)21-CH3" " |" " OH" "001/004/" "209-210ﾟC(3水和物), 204-208ﾟC (001/004)" "[α]/D=+2.4ﾟ(C 0.81 in PrOH), [α]/D=+9.4ﾟ(C 0.6 in 1-PrOH) (001/004)" "001/004/" "-OH:3400cm-1, AMIDE:1645,1535cm-1 (001/004)" "1H-NMR 0.88 or 0.84(t,J=6Hz,6H,2CH3CH2),4.89(d,J=8Hz,1H,1-H of Glc), 5.20(m,1H,CHNH),8.48(d,J=8Hz,1H,CHNH)13C-NMR 175.7(CONH), 105.5(Glc,Cl) (001/004)" "816 [M-H]-,654 [M-H-162(Glc RESIDE)]- (001/004)" "001/004/" "ヒトデ類（海星類）オニヒトデ 全体 化学合成(002)" "立体配置(002), フィトスフィンゴシンの立体配置(005)" "002/005/" "GL0189" 8.00 "1-GLUCOPYRANOSYL-2-(2-HYDROXYHEXADECANOYLAMINO)-1,3,4-DOCOSANETRIOL" "ACANTHACEREBROSIDE B" "C44H87O10N" 44.00 87.00 10.00 1.00 0.00 0.00 789.00 " (REF:001)" " Glc-O-CH2-CH-CH-CH-(CH2)17-CH3" " | | |" " NH OH OH" " |" " O=C-CH-(CH2)13-CH3" " |" " OH" "001/" "218-219ﾟC(1水和物) (001)" "[α]/D=+7.8ﾟ(C 0.81 in PrOH) (001)" "001/" "-OH:3400cm-1, AMIDE:1645,1535cm-1 (001)" "1H-NMR :0.84(t,J=6Hz,2CH3CH2),4.89(d,J=8Hz,1H,1-H of Glc), 5.20(m,1H,CHNH),8.48(d,J=8Hz,1H,CHNH) 13C-NMR:175.7(CONH), 105.4(Glc,Cl) (001)" "788 [M-H]-, 626 [M-H-162]- (001)" "001/" "ヒトデ類（海星類）オニヒトデ 全体" "GL0190" 8.00 "1-GLUCOPYRANOSYL-2-(2-HYDROXYHEXADECANOYLAMINO)-13-DOCOSENE-1,3,4-TRIOL" "ACANTHACEREBROSIDE C" "C44H85O10N" 44.00 85.00 10.00 1.00 0.00 0.00 787.00 " (REF:001)" " Glc-O-CH2-CH-CH-CH-(CH2)8-CH=CH-(CH2)7-CH3" " | | |" " NH OH OH" " |" " O=C-CH-(CH2)13-CH3" " |" " OH" "001/" "203-204ﾟC (001)" "[α]/D=+18.3ﾟ(C 1.24 in PrOH) (001)" "001/" "(KBr法) OH:3400cm-1, AMIDE:1645,1535cm-1 (001)" "1H-NMR :δ=0.84(t,J=6Hz,6H,2CH3CH2),δ=4.89(d,J=8Hz,H,1-H of Glc), δ=5.20(m,1H,CHNH),δ=8.48(d,J=8Hz,1H,CHNH) 13C-NMR:175.8(CONH), 105.4(Glc,Cl),130.3(=CH) (001)" "786 [M-H]-, 624 [(M-H)-162(GLc,RESIDUE)]- (001)" "001/" "ヒトデ類（海星類）オニヒトデ 全体" "GL0191" 8.00 "1-GLUCOPYRANOSYL-2-(2-HYDROXYDOCOSANOYLAMINO)-4,10-DIOCTADECENE-1,3-DIOL" "ACANTHACEREBROSIDE D" "C46H87O9N" 46.00 87.00 9.00 1.00 0.00 0.00 797.00 " (REF:001)" " Glc-O-CH2-CH-CH-CH=CH-(CH2)4-CH=CH-(CH2)6-CH3" " | |" " NH OH" " |" " O=C-CH-(CH2)19-CH3" " |" " OH" "001/" "198-199ﾟC (2水和物)(001)" "[α]/D=+1.1ﾟ(C 0.3 in PrOH) (001)" "001/" "(KBr法) 0H:3400cm-1, AMIDE:1645,1535cm-1 (001)" "1H-NMR :δ=0.84(t,J=6Hz,2CH3CH2),δ=4.89(d,J=8Hz,H,1H of Glc), δ=5.50(m,2H,CH=CH),δ=5.90(m,2H,CH=CH),δ=8.38(d,J=8Hz,1H,CHNH) 13C-NMR:175.7(CONH),131.1(=CH),129.9(=CH),132.2(-CHOH-CH=),硫酸基を持つｶﾞﾝｸﾞﾘｵｼﾄﾞの最初の構造(090)" "796 [M-H]-, 634 [(M-H)-162(GLc,RESIDUE)]- (001)" "001/" "ヒトデ類（海星類）オニヒトデ 全体" "GL0192" 8.00 "1-GLUCOPYRANOSYL-2-(2-HYDROXYTRICOSANOYLAMINO)-4,10-DIOCTADECENE-1,3-DIOL" "ACANTHACEREBROSIDE E" "C47H89O9N" 47.00 89.00 9.00 1.00 0.00 0.00 811.00 " (REF:001)" " Glc-O-CH2-CH-CH-CH=CH-(CH2)4-CH=CH-(CH2)6-CH3" " | |" " NH OH" " |" " O=C-CH-(CH2)20-CH3" " |" " OH" "001/" "194-195ﾟC (3水和物)(001)" "[α]/D=+1.0ﾟ(C 0.3 in PrOH) (001)" "001/" "(KBr法) OH:3400cm-1, AMIDE:1645,1535cm-1 (001)" "1H-NMR :δ=0.84(t,J=6Hz,2CH3CH2),δ=4.89(d,J=8Hz,H,1H of Glc), δ=5.50(m,2H,CH=CH),δ=5.90(m,2H,CH=CH),δ=8.38(d,J=8Hz,1H,CHNH) 13C-NMR:175.7(CONH),105.5(Glc,lc),131.1(=CH),129.9(=CH),131.9(-CHOH-CH=), 132.1(-CHOH-CH=CH-) (001)" "810 [M-H]-, 648[M-H-162(GLc,RESIDUE)]- (001)" "001/" "ヒトデ類（海星類）オニヒトデ 全体" "GL0193" 8.00 "1-GLUCOPYRANOSYL-2-(2-HYDROXYTETRACOSANOYLAMINO)-4,10-DIOCTADECENE-1,3-DIOL" "ACANTHACEREBROSIDE F" "C48H91O9N" 48.00 91.00 9.00 1.00 0.00 0.00 825.00 " (REF:001)" " Glc-O-CH2-CH-CH-CH=CH-(CH2)4-CH=CH-(CH2)6-CH3" " | |" " NH OH" " |" " O=C-CH-(CH2)21-CH3" " |" " OH" "001/" "193-194ﾟC (2水和物)(001)" "[α]/D=+1.2ﾟ(C 0.5 in PrOH) (001)" "001/" "(KBr法) OH:3400cm-1, AMIDE:1645,1535cm-1 (001)" "1H-NMR :δ=0.84(t,J=6Hz,2CH3CH2),δ=4.89(d,J=8Hz,H,1H of Glc), δ=5.50(m,2H,CH=CH),δ=5.90(m,2H,CH=CH),δ=8.38(d,J=8Hz,1H,CHNH) 13C-NMR:175.7(CONH),105.5(Glc,lc),131.1(=CH),129.9(=CH),132.1(-CHOH-CH=), 131.9(-CHOH-CH=CH-) (001)" "824 [M-H]-, 662 [M-H-162(GLc,RESIDUE)]- (001)" "001/" "ヒトデ類（海星類）オニヒトデ 全体" "GL0194" 8.00 "1-(IV3-α-N-ACETYLGALACTOSAMINYL-GLOBOTETRAOSYL-OXY)-2-ACYLAMINO-3,4-BUTANEDIOL" "1" "C54H97O29N3" 54.00 97.00 29.00 3.00 0.00 0.00 1251.00 "GalNAcα1-3GalNAcβ1-3Galα1-4Galβ1-4Glcβ1 (REF:001)" " ｜" " O" " ｜" " CH2-CH-CH-CH2" " ｜ ｜ ｜" " OH OH NH" " ｜" " O=C-(CH2)14〜22-CH3" "001/" "ミセル形成(5mg/ml水溶液，沈降定数 5.1S) (002)" "002/" "2850cm-1, 2920cm-1（メチレン）の著明な減少．1540cm-1, 1640cm-1（アミド結合）の存在．(001)" "0.88ppm（末端メチル基）の存在 (1H-NMR) (001)" "001/" "ヤギ赤血球膜由来，オゾン分解と還元により調製 (001)" "001/" "溶血活性（ヒツジ赤血球に対して HL50=11.0μM)(001) FORSSMAN抗原，免疫原性(003)" "001/003/" "GL0195" 8.00 "1-(IV3-α-N-ACETYLGALACTOSAMINYL-GLOBOTETRAOSYL-OXY)-2-(15-HYDROXY- PENTADECANOYLAMINO)-3,4-BUTANEDIOL" "1" "C53H95O30N3" 53.00 95.00 30.00 3.00 0.00 0.00 1253.00 "GalNAcα1-3GalNAcβ1-3Galα1-4Galβ1-4Glcβ1" " ｜ (REF:001)" " O" " ｜" " CH2-CH-CH-CH2" " ｜ ｜ ｜" " OH OH NH" " ｜" " O=C-(CH2)13-CH2-OH" "001/" "ミセル形成(5mg/ml水溶液，沈降定数 4.5S) (002)" "002/" "2850cm-1，2920cm-1（メチレン）の著明な減少．1540cm-1，1640cm-1（アミド結合）の存在(001)" "0.88ppm（末端メチル基）の消失（1H-NMR）．(001)" "001/" "ヤギ赤血球膜由来，オゾン分解と還元により調製 (001)" "001/" "溶血活性を示さない(001),FORSSMAN抗原，免疫原性(003)" "001/003/" "GL0196" 8.00 "IV3-N-GLYCOLYLNEURAMINOSYLNEOLACTOTETRAOSYLCERAMIDE" "SIALOSYLPARAGLOBOSIDE" "4" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " NeuGcα2-3Galβ1-4GalNAcβ1-3Galβ1-4Glcβ1-1Cer (REF:006)" "006/" "[α]19/D=-2.8 (C=0.81 IN METHANOL)(006)" "006/" "1640cm-1, 1540cm-1（アミド結合），890cm-1（β-グリコシド結合）など．(006)" "006/" "ウシ赤血球膜(006)，ウシ脾(009)" "006/009/" "MYCOPLASMA PNEUMONIAE のヒト赤血球への吸着を阻害 (010),H-D抗原活性(011)" "010/011/" "GL0197" 8.00 "N-ACETYLGALACTOSAMINYLβ1-4GALACTOSYLβ1-4 GLUCOSYL CERAMIDE-V3 SULFATE" "Gg3CerV3-SULFATE,SM2b" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:073)" " HSO3-3GalNAcβ1-4GaLβ1-1Cer" " s3Kb4Hb4Gb1C" "073/" "1240(S=O), 810(C-O-S) cm-1(073)" "1H 1次元とDQF-cosy. Gg3Cerと比較してβGalNAcのH-3が0.579ppmと最も大きく違うことからHSO3-がH-3に結合していることが分かる｡" "LSIMS(-) [M-H]-=1273, [OSO3H]-=97 を検出｡ 高エネルギーCID スペクトラムにより[M-H]-イオンからグリコシド結合の逐次解裂イオンを検出｡ 低エネルギーCID MS/MSでは[(HSO3-O-HexNAc)-2H]-=282 のみを検出｡(073)" "073/" "ラット(Sprague Dawley)腎臓(073)" "073/" "TLC CMW(Ca2+) 60:40:9 で Gg3CerとGg4Cerの中間,SM2aよりやや下｡" "GL0198" 8.00 "GALACTOSYLβ1-3(N-ACETYLNEURAMINYLα2-6) N-ACETYLGALACTOSAMINYLβ1-4GALACTOSYLβ1-4GLUCOSYLCERAMIDE" "V6NeuAc-GgOse4Cer, GM1α" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:074)" " NeuAcα2" " |" " 6" " Galβ1-3GalNAcβ1-4Galβ1-4Galβ1-Cer" " Hb3(Na6)Kb4Hb4Gb1C" "074/" "FAB-MS(-) [M-H]-=1572(d20:1/C18:0に対応), [M-H]-=1544(d18:1/C18:0)に対応｡ (074)" "074/" "ウシ脳(074)" "074/" "抗コリン作動性ニューロン抗体(anti-Chol-1)と反応｡(074)" "074/" "TLC (C:M:12mM MgCl2=5:4:1)で GM1aとGD1aとの中間(074)" "074/" "GL0199" 8.00 "GALACTOSYLβ1-3(N-ACETYLNEURAMINYLα2-6)N-ACETYLGALACTOSAMINYLβ1-4(N-ACETYLNEURAMINYLα2-3)GALACTOSYLβ1-4GLUCOSYLCERAMIDE" "V6NeuAc,U3NeuAc-GgOse4Cer, GD1aα" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:074)" " NeuAcα2" " |" " 6" " Galβ1-3GalNAcβ1-4Galβ1-4Glcβ1-Cer" " 3" " |" " NeuAcα2" " Hb3(Na6)Kb4(Na3)Hb4GblC" "074/" "FAB-MS(-) [M-H+Na-H]-=1858(d18:1/C18:0のセラミドに対処)を検出｡(074)" "074/" "ウシ脳(074)" "074/" "抗コリン作動性ニューロン抗体(anti-Chol-1)と反応｡(074)" "074/" "TLC (C:M:12mM MgCl2=5:4:1)で GD1bの少し上(074)" "074/" "GL0200" 8.00 "GALACTOSYLβ1-3(N-ACETYLNEURAMINYLα2-6)N-ACETYLGALACTOSAMINYLβ1-4(N-GLYCOLYLNEURAMINYLα2-8N-ACETYLNEURAMINYLα2-3))GALACTOSYLβ1-4GLUCOSYLCERAMIDE" "V6NeuAc,U3NeuAc-NeuGc･GgOse4Cer,GT1bα" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:074)" " NeuAcα2" " |" " 6" " Galβ1-3GalNAcβ1-4Galβ1-4Glcβ1-Cer" " 3" " |" " NeuAcα2 Hb3(Nab)Kb4(Oa8Na3)Hb4Gb1C" " 8" " |" " NeuGcα2" "074/" "FAB-MS(-) [M-H]-=2170(d20:1/C18:0のセラミドに対応)と [M-H]-=2142(d18:1/C18:0)を検出｡ Galに結合した２つのシアル酸が脱離したイオンm/z=1544と1572が強く出る(074)" "074/" "ウシ脳(074)" "074/" "抗コリン作動性ニューロン抗体(anti-Chol-1)と反応｡(074)" "074/" "TLC (C:M:12mM MgCl2=5:4:1)で GT1bとGQ1bの中間(074)" "074/" "GL0201" 8.00 "N-ACETYLNEURAMINYLα2-3GALACTOSYLβ1-4(FUCOSYLα1-3)N-ACETYLGLUCOSAMINYLβ1-3GALACTOSYLβ1-4N-ACETYLGLUCOSAMINYLβ1-3GALACTOSYLβ1-4GLUCOSYLCERAMIDE" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:075)" " NeuAcα2-3Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ1-3Galβ1-4Glcβ1-1Cer" " 3" " |" " Fucα1" " Na3Hb4(Fa3)Jb3Hb4Jb3Hb4GblC" "075/" "完全メチル化した試料のFAB-MS(+) [M+Na]+=2443,[M+H]+=2421を検出｡(075)" "075/" "ヒト顆粒白血球(075)" "075/" "モノクローナル抗体CSLEX1(SIALYL Lewisx構造を認識)と反応する｡ CDW65 (VIM-2特異的)とは反応しない｡ CD15 (Sialyl Lewisx 自身を認識)とは反応しない｡ AM3 (Sialyl Lewisx sequenceを認識)と強く反応する｡(075)" "075/" "セラミドの脂肪酸 C16:0, スフィンゴシン C18(075)" "075/" "GL0202" 8.00 "N-ACETYLNEURAMINYLα2-3GALACTOSYLβ1-4N-ACETYLGLUCOSAMINYLβ1-3GALACTOSYLβ1-4(FUCOSYLα1-3)N-ACETYLGLUCOSAMINYLβ1-3GALACTOSYLβ1-4N-ACETYLGLUCOSAMINYLβ1-3GALACTOSYLβ1-4GLUCOSYLCERAMIDE" "[3NeuAcFuc-nLcOse8Cer" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:075)" " NeuAcα2-3Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ1ｲ" " 3 ｮ｢｢｢｢｢｢｢ｺ" " | ｶ3Galβ1-4GKβ1-Cer" " Fucα1" " Na3Hb4Jb3Hb4(Fa3)Jb3Hb4Jb3Hb4Gb1C" "075/" "完全メチル化物のFAB-MS(+) スペクトラムは未掲載｡文章のみ [MH]+=2980,[Mna]+=3002,[NeuAcGalG1cNAc]+=1448, TLC上分離する近接スポットは,[MH]+=2870,[Mna]+=2892を与える｡(脂肪酸の相違)(075)" "075/" "ヒト顆粒白血球(075)" "075/" "モノクローナル抗体CSLEX1と反応しない｡ CDW65 と反応する｡(VIM-2 motifを有する)(075)" "075/" "セラミドの脂肪酸 24:0 - C18 スフィンゴシン、 セラミドの脂肪酸16:0 - C18 スフィンゴシン (075)" "075/" "GL0203" 8.00 "N-ACETYLNEURAMINYLα2-6GLUCOSYLCERAMIDE" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:076)" " NeuAcα2-6Glcβ1-Cer" " Na6Gb1C" "076/" "1H-NMR Glc,H-1,J1.2=84Hz(δ=1.14ppm) β結合｡(076)" "FAB-MS(-) [M-H]-=1033, 1047, 1061, 1075, 1089 それぞれ脂肪酸 C18:1, C19:1, C20:1, C21:1, C22:1 に対応｡ 長鎖塩基は t18:0 (076)" "076/" "ウニ(Hemicentrotus Pulcherrimus)の精子(076)" "076/" "脂肪酸組成 C20:1 30mol%, C21:1 20mol%, C22:1 30mol%, C16:0,C16:1,C18:0,C18:1,C19:1,C20:0 5mol% 以下(076)" "076/" "GL0204" 8.00 "N-ACETYLNEURAMINYLα2-8N-ACETYLNEURAMINYLα2-6GLUCOSYLCERAMIDE" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:076)" " NeuAcα2-8NeuAcα2-6Glcβ1-Cer" " Na8Na6Gb1C" "076/" "1H-NMR GlcのH-1,J1.2=7.3Hz(δ=4.12ppm) β結合｡" "FAB-MS(-) [M-H]-=1325, 1339, 1353, 1367, 1381(脂肪酸 C18:1, C19:1, C20:1, C21:1, C22:1 に対応｡)長鎖塩基は t18:0 (076)" "076/" "ウニ(Hemicentrotus Pulcherrimus)の精子(076)" "076/" "GL0205" 8.00 "N-ACETYLNEURAMINYLα2-8N-ACETYLNEURAMINYLα2-8N-ACETYLNEURAMINYLα2-6GLUCOSYLCERAMIDE" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:076)" " NeuAcα2-8NeuAcα2-8NeuAcα2-6Glcβ1-Cer" " Na8Na8Na6Gb1C" "076/" "完全メチル化物のFAB-MS(+)で, NeuAc=376,　(NeuAc)2=737, (NeuAc)3=1099が検出された｡ 2H-アセチル化物では, ラクトン化した(Neu5Ac)3(Hex),Cerに相当するイオンを検出｡(076)" "076/" "ウニ(Hemicentrotus Pulcherrimus)の精子(076)" "076/" "GL0206" 8.00 "N-ACETYLNEURAMINYLα2-6GLUCOSYLCERAMIDE-II8SULFATE" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:076)" " HSO3-8NeuAcα2-6Glcβ1-Cer" " s8Na6Gb1C" "076/" "1H-NMR GlcのH-1, δ4.10ppm, J1.2=8.4Hz(β結合),　NeuAcのH-3eq,δ2.48ppm,H-3axδ1.45ppm(α結合)(076)" "[M-H]-=1113, 1127, 1141, 1155, 1169(それぞれセラミドの脂肪酸 C18:1, C19:1, C20:1, C21:1, C22:1に対応｡ 長鎖塩基はt18:0)(076)" "076/" "ウニ(Hemicentrotus Pulcherrimus)の精子(076)" "076/" "GL0207" 8.00 "N-ACETYLNEURAMINYLα2-8N-ACETYLNEURAMINYLα2-8N-ACETYLNEURAMINYLα2-8N-ACETYLNEURAMINYLα2-6GLUCOSYLCERAMIDE" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:076)" " NeuAcα2-8NeuAcα2-8NeuAcα2-8NeuAcα2-6Glcβ1-Cer" " Na8Na8Na8Na6Gb1C" "076/" "1H-NMR Glc, H-1, δ4.10ppm, J1.2=8.4Hz｡ NeuAc, H-3eq, 2.48ppm, H-3ax, 1.45ppm(076)" "FAB-MS(-) [M-H]-=1113, 1127, 1141, 1155, 1169(脂肪酸 C18:1, C19:1, C20:1, C21:1, C22:1に対応｡ 長鎖塩基はt18:0)(076)" "076/" "ウニ(Hemicentrotus Pulcherrimus)の精子(076)" "076/" "GL0208" 8.00 "N-ACETYLNEURAMINYLα2-8N-ACETYLNEURAMINYLα2-6GLUCOSYLCERAMIDE-III8SULFATE" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:076)" " HSO3-8NeuAcα2-8NeuAcα2-6Glcβ1-Cer" " s8Na8Na6Gb1C" "076/" "1H-NMR Glc, H-1, δ4.08ppm, J1.2=7.7Hz｡ ２つのNeuAcのH-3のケミカルシフトはどちらのNeuAc由来かは帰属できないが(H-3eq,H-3ax)は(2.26ppm, 1.45)または(2.42,1.35)" "FAB-MS(-) [M-H]-=1387, 1401, 1415, 1429, 1443(脂肪酸 C18:1, C19:1, C20:1, C21:1, C22:1に対応。 長鎖塩基はt18:0｡ ラクトン化したものに対応するM/Zを検出｡(076)" "076/" "ウニ(Hemicentrotus Pulcherrimus)の精子(076)" "076/" "GL0209" 8.00 "1,2-DIACYL-1-3α-D-GLUCURONOPYRANOSYL-SN-GLYCEROL-TAURINEAMIDE" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:077)" " CONHCH2CH2SO2O-" " ｶｽ O" " ／OH ＼" " ﾉｵ ｬ" " HO ｼｻ O｢｢ｲ" " HO H ﾞ｢OCOR" " ｶ｢OCOR" "077/" "Budding seawater bacterium Hyphomonas jannaschiana VP-2T株(ATCC 33883T)(077)" "077/" "脂肪酸組成 n-14:0, 2mol%; n-15:0,3%; n-16:0,19%; cis-16:1ω7,6%; n-17:0,4%; n-18:0,15%; cis-18:ω7,44%; n-19:0,7% (077)" "077/" "GL0210" 8.00 "GALACTOSYLα1-2INOSITOL1-PHOSPHOCERAMIDE" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:078)" " O" " ｾ" " Galα1-2Ins-P-O-Cer" " |" " OH" " (Galα1-2Ins(1→)-P-Cer)" "078/" "OH- 吸収 3400,1040cm-1, アミドI 1650cm-1, アミドII 1550cm-1, リン酸 1220cm-1(078)" "Gal, H-1, 5.05ppm(J1.2=3.30Hz)(078)" "FAB-MS(-) [M-H]-=1070, 1056, P-Cer由来のイオン M/Z = 746,732(078)" "078/" "ブタ回虫 Ascaris suum(078)" "078/" "セラミドの脂肪酸 直鎖酸 16:0,1.4%; 18:0,1.7%; 24:0,25.1% 2-OH酸 22:0,5.6%; 23:0,3%; 24:0,63.2% 長鎖塩基 br.d 17:0,30.7%; d18:0,69.3%" "GL0211" 8.00 "GALACTOSYLβ1-4(FUCOSYLα1-3)GLUCOSYLβ1-3(GALACTOSYLβ1-6)GALACTOSYLCERAMIDE" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:079)" " Galβ1-4(Fucα1-3)Glcβ1-3(Galβ1-6)Galβ1-1Cer" " Hb4(Fa3)Gb3(Hb6)Hb1C" "079/" "1H-NMR １次元とTOCSY (079)" "セラミド組成の違いでTLC上分離する２つの成分についての FAB-MS(-)で [M-H]-=1472,1498 (C26:0-d18:0,C28:1,C28:0-D18:0)と1488,1514(C26:-t18:0,C28:1-t18:0)(079)" "079/" "マンソン裂頭条虫(Spirometra erinacei)のプレロセルコイド(079)" "079/" "TLCで分離する２つのバンドがあり, 糖鎖構造は同一｡ 上のバンドのセラミドは, C28:1,30.2%;C26:0,21.9%; とスフィンガニン(45.1%),4-D-ヒドロキシスフィンガニン(54.9%)｡ 下のバンドは, C28:0,21.7%, C26:0,10.3%, C18:1,13.8%; C16:0,11.0%と 4-D-ヒドロキシスフィンガニン(90.3%)(079)" "079/" "GL0212" 8.00 "9-O-ACETYL N-GLYCOLYLNEURAMINYLα2-3GALACTOSYLβ1-4GLUCOSYLCERAMIDE" "9-O-Ac GM3(GC)" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:080)" " Aco-aNeuGcα2-3Galβ1-4Glcβ1-1Cer" " t9Oa3Hb4GblC" "080/" "NeuGcのC-9のメチレンプロトンが低磁場へシフト(H-9a,3.95ppm, H-9b,4.22ppm)(080)" "FAB-MS(-) [M-H-]=1321,[HexHexCer-H]-=972(080)" "080/" "ウマ赤血球(080)" "080/" "6'-O-AcGM3(Gc)との混合物として得られた｡ シアリダーゼ処理, 機器分析により両者が存在することを証明｡ セラミド:: C24:0,32.2%; d18:1,98.7% (080)" "080/" "GL0213" 8.00 "N-GLYCOLYLα2-3(6-O-ACETYL)GALACTOSYLβ1-4GLUCOSYLCERAMIDE" "6'-O-Ac GM3(GC)" 0.00 0.00 0.00 0.00 0.00 0.00 0.00 " (REF:080)" " NeuGcα2-3(6-O-Ac)Galβ1-4Glcβ1-1Cer" " Oa3(t6)Hb4GlC" "080/" "GalのC-6のメチレンプロトンが低磁場へシフト(080)" "FAB-MS(-) [Ac-HexHexCer-H]-=1014が存在(080)" "080/" "ウマ赤血球(080)" "080/" "9-O-Ac-GM3(Gc)との混合物として得られた｡ セラミド C24:0,26.8%; d18:1,97.5% (080)" "080/"